Compounds > pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid
Page last updated: 2024-09-20

pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid

Description

5'-phosphonatopyridoxal-6-azobenzene-2,4-disulfonate : An organophosphate oxoanion obtained by deprotonation of the phospho and sulfo groups of 5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid: a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid : An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5034182
CHEBI ID91082
MeSH IDM0208738
PubMed CID4881
CHEMBL ID69234
CHEMBL ID3305983
CHEMBL ID1437958
CHEBI ID34941
SCHEMBL ID5287746
SCHEMBL ID13624677
MeSH IDM0208738

Synonyms (39)

Synonym
tocris-0625
NCGC00024691-01 ,
NCGC00024691-02
NCGC00024691-03
CCG-205058
CHEBI:91082
ppads(4-)
5'-phosphonatopyridoxal-6-azobenzene-2,4-disulfonate
4-[[4-formyl-5-hydroxy-6-methyl-3-(phosphonatooxymethyl)pyridin-2-yl]diazenyl]benzene-1,3-disulfonate
NCGC00024691-06
gtpl1725
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid
1,3-benzenedisulfonic acid, 4-((4-formyl-5-hydroxy-6-methyl-3-((phosphonooxy)methyl)-2-pyridinyl)azo)-
4-((4-formyl-5-hydroxy-6-methyl-3-((phosphonooxy)methyl)-2-pyridinyl)azo)-1,3-benzenedisulfonic acid
LOPAC0_000978
pyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid
ppads
149017-66-3
NCGC00163313-01
chebi:34941 ,
CHEMBL69234 ,
L000489
nsc_6093163
cas_149017-66-3
bdbm85043
unii-l6k2lj9bjk
l6k2lj9bjk ,
SCHEMBL5287746
SCHEMBL13624677
5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid
4-({4-formyl-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]pyridin-2-yl}diazenyl)benzene-1,3-disulfonic acid
CHEMBL3305983
CHEMBL1437958
4-[[4-formyl-5-hydroxy-6-methyl-3-(phosphonooxymethyl)pyridin-2-yl]diazenyl]benzene-1,3-disulfonic acid
Q27116327
Q7120083
DTXSID401019090
4-(2-(4-formyl-5-hydroxy-6-methyl-3-((phosphonooxy)methyl)-2-pyridinyl)diazenyl)-1,3-benzenedisulfonic acid
bdbm50540409

Roles (1)

RoleDescription
purinergic receptor P2X antagonistAn antagonist at purinergic P2X receptors
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (8)

ClassDescription
organophosphate oxoanionAn organic phosphoric acid derivative in which one or more oxygen atoms of the phosphate group(s) has been deprotonated.
organosulfonate oxoanionAn organic anion obtained by deprotonation of the sufonate group(s) of any organosulfonic acid.
arenesulfonic acidOrganic derivatives of sulfonic acid in which the sulfo group is linked directly to carbon of an aryl group.
azobenzenesAny member of the wide class of molecules that share the core azobenzene structure, comprising two phenyl rings linked by a N=N double bond, which may have different functional groups extending from the rings.
methylpyridinesAny member of the class of pyridines that carries at least one methyl substituent.
monohydroxypyridineA hydroxypyridine carrying a single hydroxy substituent.
pyridinecarbaldehyde
organic phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (47)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency31.62280.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency16.09920.004023.8416100.0000AID485290; AID489007
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency22.38720.177814.390939.8107AID2147
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.63100.100020.879379.4328AID588453
USP1 protein, partialHomo sapiens (human)Potency44.66840.031637.5844354.8130AID504865
Microtubule-associated protein tauHomo sapiens (human)Potency22.38720.180013.557439.8107AID1460
regulator of G-protein signaling 4Homo sapiens (human)Potency0.07520.531815.435837.6858AID504845
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency23.77810.035520.977089.1251AID504332
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.01260.00255.840031.6228AID899
ras-related protein Rab-9AHomo sapiens (human)Potency12.58930.00022.621531.4954AID485297
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency30.13130.425612.059128.1838AID504536
caspase-1 isoform alpha precursorHomo sapiens (human)Potency31.62280.000311.448431.6228AID900
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency31.62280.316212.765731.6228AID881
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency31.62280.00638.235039.8107AID881
Caspase-7Homo sapiens (human)Potency31.62283.981118.585631.6228AID889
Ataxin-2Homo sapiens (human)Potency25.11890.011912.222168.7989AID588378
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency31.62280.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency12.58930.004023.8416100.0000AID485290
phosphopantetheinyl transferaseBacillus subtilisPotency25.11890.141337.9142100.0000AID1490
Microtubule-associated protein tauHomo sapiens (human)Potency7.07950.180013.557439.8107AID1460
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency28.18380.011212.4002100.0000AID1030
67.9K proteinVaccinia virusPotency22.38720.00018.4406100.0000AID720579
glucocerebrosidaseHomo sapiens (human)Potency19.95260.01268.156944.6684AID2101
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.54810.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency25.11890.354828.065989.1251AID504847
DNA polymerase kappa isoform 1Homo sapiens (human)Potency8.91250.031622.3146100.0000AID588579
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency35.48130.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
P2X purinoceptor 1Rattus norvegicus (Norway rat)IC50 (µMol)33.19970.00030.23031.0000AID150300; AID165064; AID1654778
P2Y purinoceptor 1Meleagris gallopavo (turkey)IC50 (µMol)16.60004.19006.04258.4600AID150644
P2X purinoceptor 2Rattus norvegicus (Norway rat)IC50 (µMol)1.60000.69001.65804.0000AID150303
P2X purinoceptor 3Rattus norvegicus (Norway rat)IC50 (µMol)120.12000.01000.08260.2400AID150305; AID165065
P2X purinoceptor 1Mus musculus (house mouse)IC50 (µMol)0.09900.03000.06450.0990AID1059230
P2X purinoceptor 4Rattus norvegicus (Norway rat)IC50 (µMol)251.30002.45002.50002.6000AID150309; AID150310
P2X purinoceptor 6Rattus norvegicus (Norway rat)IC50 (µMol)251.00002.00002.00002.0000AID150311; AID150312
P2X purinoceptor 3Homo sapiens (human)IC50 (µMol)0.24000.00000.20301.5136AID1059229
P2X purinoceptor 5Homo sapiens (human)IC50 (µMol)8.45008.45008.45008.4500AID1884359
P2X purinoceptor 4Homo sapiens (human)IC50 (µMol)16.80000.15602.93526.1000AID150307; AID1884357
P2X purinoceptor 7Homo sapiens (human)IC50 (µMol)1.18000.00080.24525.0000AID1059221
P2X purinoceptor 2Homo sapiens (human)IC50 (µMol)2.02000.00830.43452.0200AID1884355
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mu-type opioid receptorHomo sapiens (human)EC50 (µMol)100.00000.00000.32639.4000AID150172
Delta-type opioid receptorHomo sapiens (human)EC50 (µMol)100.00000.00000.43328.3000AID150172
Kappa-type opioid receptorHomo sapiens (human)EC50 (µMol)100.00000.00000.22448.9900AID150172
P2Y purinoceptor 2Homo sapiens (human)EC50 (µMol)10.00000.00560.682810.0000AID150321
P2X purinoceptor 1Rattus norvegicus (Norway rat)EC50 (µMol)0.09900.05402.761310.0000AID152481
P2Y purinoceptor 1Homo sapiens (human)EC50 (µMol)9.60000.00130.42027.2000AID150331; AID150464
P2X purinoceptor 2Rattus norvegicus (Norway rat)EC50 (µMol)12.00001.50001.50001.5000AID150145
P2X purinoceptor 4Rattus norvegicus (Norway rat)EC50 (µMol)10.00002.30006.566710.0000AID150165
P2X purinoceptor 5Rattus norvegicus (Norway rat)EC50 (µMol)2.60000.60002.05004.0000AID150170
P2X purinoceptor 6Rattus norvegicus (Norway rat)EC50 (µMol)100.00000.60000.95001.3000AID150172
P2Y purinoceptor 4Homo sapiens (human)EC50 (µMol)10.00000.02301.362310.0000AID150627
P2X purinoceptor 3Homo sapiens (human)EC50 (µMol)0.97000.24002.80229.2000AID150151; AID150156
P2X purinoceptor 4Homo sapiens (human)EC50 (µMol)10.00001.00005.500010.0000AID150161
P2Y purinoceptor 12Rattus norvegicus (Norway rat)EC50 (µMol)100.00000.00111.09044.0000AID150495
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (231)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
proteolysisCaspase-7Homo sapiens (human)
apoptotic processCaspase-7Homo sapiens (human)
heart developmentCaspase-7Homo sapiens (human)
response to UVCaspase-7Homo sapiens (human)
protein processingCaspase-7Homo sapiens (human)
protein catabolic processCaspase-7Homo sapiens (human)
defense response to bacteriumCaspase-7Homo sapiens (human)
fibroblast apoptotic processCaspase-7Homo sapiens (human)
striated muscle cell differentiationCaspase-7Homo sapiens (human)
neuron apoptotic processCaspase-7Homo sapiens (human)
protein maturationCaspase-7Homo sapiens (human)
lymphocyte apoptotic processCaspase-7Homo sapiens (human)
cellular response to lipopolysaccharideCaspase-7Homo sapiens (human)
cellular response to staurosporineCaspase-7Homo sapiens (human)
execution phase of apoptosisCaspase-7Homo sapiens (human)
positive regulation of plasma membrane repairCaspase-7Homo sapiens (human)
positive regulation of neuron apoptotic processCaspase-7Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
intracellular monoatomic ion homeostasisP2Y purinoceptor 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
positive regulation of mucus secretionP2Y purinoceptor 2Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 2Homo sapiens (human)
blood vessel diameter maintenanceP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
positive regulation of protein phosphorylationP2Y purinoceptor 1Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayP2Y purinoceptor 1Homo sapiens (human)
monoatomic ion transportP2Y purinoceptor 1Homo sapiens (human)
cell surface receptor signaling pathwayP2Y purinoceptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayP2Y purinoceptor 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationP2Y purinoceptor 1Homo sapiens (human)
glial cell migrationP2Y purinoceptor 1Homo sapiens (human)
regulation of cell shapeP2Y purinoceptor 1Homo sapiens (human)
response to mechanical stimulusP2Y purinoceptor 1Homo sapiens (human)
negative regulation of norepinephrine secretionP2Y purinoceptor 1Homo sapiens (human)
signal transduction involved in regulation of gene expressionP2Y purinoceptor 1Homo sapiens (human)
platelet activationP2Y purinoceptor 1Homo sapiens (human)
positive regulation of inositol trisphosphate biosynthetic processP2Y purinoceptor 1Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 1Homo sapiens (human)
eating behaviorP2Y purinoceptor 1Homo sapiens (human)
positive regulation of monoatomic ion transportP2Y purinoceptor 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIP2Y purinoceptor 1Homo sapiens (human)
positive regulation of hormone secretionP2Y purinoceptor 1Homo sapiens (human)
establishment of localization in cellP2Y purinoceptor 1Homo sapiens (human)
positive regulation of penile erectionP2Y purinoceptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeP2Y purinoceptor 1Homo sapiens (human)
response to growth factorP2Y purinoceptor 1Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 1Homo sapiens (human)
cellular response to purine-containing compoundP2Y purinoceptor 1Homo sapiens (human)
protein localization to plasma membraneP2Y purinoceptor 1Homo sapiens (human)
relaxation of muscleP2Y purinoceptor 1Homo sapiens (human)
blood vessel diameter maintenanceP2Y purinoceptor 1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationP2Y purinoceptor 1Homo sapiens (human)
regulation of synaptic vesicle exocytosisP2Y purinoceptor 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 4Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationP2Y purinoceptor 4Homo sapiens (human)
transepithelial chloride transportP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 4Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 4Homo sapiens (human)
cellular response to prostaglandin E stimulusP2Y purinoceptor 4Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationP2Y purinoceptor 4Homo sapiens (human)
regulation of synaptic vesicle exocytosisP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 4Homo sapiens (human)
response to hypoxiaP2X purinoceptor 3Homo sapiens (human)
signal transductionP2X purinoceptor 3Homo sapiens (human)
neuromuscular synaptic transmissionP2X purinoceptor 3Homo sapiens (human)
response to heatP2X purinoceptor 3Homo sapiens (human)
response to coldP2X purinoceptor 3Homo sapiens (human)
response to mechanical stimulusP2X purinoceptor 3Homo sapiens (human)
response to carbohydrateP2X purinoceptor 3Homo sapiens (human)
positive regulation of calcium ion transport into cytosolP2X purinoceptor 3Homo sapiens (human)
urinary bladder smooth muscle contractionP2X purinoceptor 3Homo sapiens (human)
peristalsisP2X purinoceptor 3Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 3Homo sapiens (human)
regulation of synaptic plasticityP2X purinoceptor 3Homo sapiens (human)
behavioral response to painP2X purinoceptor 3Homo sapiens (human)
positive regulation of calcium-mediated signalingP2X purinoceptor 3Homo sapiens (human)
sensory perception of tasteP2X purinoceptor 3Homo sapiens (human)
establishment of localization in cellP2X purinoceptor 3Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 3Homo sapiens (human)
protein homotrimerizationP2X purinoceptor 3Homo sapiens (human)
cellular response to ATPP2X purinoceptor 3Homo sapiens (human)
inorganic cation transmembrane transportP2X purinoceptor 3Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 3Homo sapiens (human)
chloride transportP2X purinoceptor 5Homo sapiens (human)
signal transductionP2X purinoceptor 5Homo sapiens (human)
nervous system developmentP2X purinoceptor 5Homo sapiens (human)
positive regulation of calcium ion transport into cytosolP2X purinoceptor 5Homo sapiens (human)
response to ATPP2X purinoceptor 5Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 5Homo sapiens (human)
osteoclast maturationP2X purinoceptor 5Homo sapiens (human)
positive regulation of calcium-mediated signalingP2X purinoceptor 5Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 5Homo sapiens (human)
monoatomic anion transmembrane transportP2X purinoceptor 5Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 5Homo sapiens (human)
regulation of ruffle assemblyP2X purinoceptor 4Homo sapiens (human)
tissue homeostasisP2X purinoceptor 4Homo sapiens (human)
regulation of sodium ion transportP2X purinoceptor 4Homo sapiens (human)
response to ischemiaP2X purinoceptor 4Homo sapiens (human)
signal transductionP2X purinoceptor 4Homo sapiens (human)
regulation of blood pressureP2X purinoceptor 4Homo sapiens (human)
positive regulation of calcium ion transport into cytosolP2X purinoceptor 4Homo sapiens (human)
negative regulation of cardiac muscle hypertrophyP2X purinoceptor 4Homo sapiens (human)
neuronal action potentialP2X purinoceptor 4Homo sapiens (human)
sensory perception of painP2X purinoceptor 4Homo sapiens (human)
calcium-mediated signalingP2X purinoceptor 4Homo sapiens (human)
positive regulation of prostaglandin secretionP2X purinoceptor 4Homo sapiens (human)
response to ATPP2X purinoceptor 4Homo sapiens (human)
monoatomic ion transmembrane transportP2X purinoceptor 4Homo sapiens (human)
response to fluid shear stressP2X purinoceptor 4Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 4Homo sapiens (human)
endothelial cell activationP2X purinoceptor 4Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationP2X purinoceptor 4Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processP2X purinoceptor 4Homo sapiens (human)
behavioral response to painP2X purinoceptor 4Homo sapiens (human)
response to axon injuryP2X purinoceptor 4Homo sapiens (human)
positive regulation of calcium-mediated signalingP2X purinoceptor 4Homo sapiens (human)
regulation of chemotaxisP2X purinoceptor 4Homo sapiens (human)
sensory perception of touchP2X purinoceptor 4Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionP2X purinoceptor 4Homo sapiens (human)
membrane depolarizationP2X purinoceptor 4Homo sapiens (human)
positive regulation of calcium ion transportP2X purinoceptor 4Homo sapiens (human)
regulation of cardiac muscle contractionP2X purinoceptor 4Homo sapiens (human)
relaxation of cardiac muscleP2X purinoceptor 4Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 4Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 4Homo sapiens (human)
cellular response to zinc ionP2X purinoceptor 4Homo sapiens (human)
cellular response to ATPP2X purinoceptor 4Homo sapiens (human)
apoptotic signaling pathwayP2X purinoceptor 4Homo sapiens (human)
positive regulation of microglial cell migrationP2X purinoceptor 4Homo sapiens (human)
positive regulation of endothelial cell chemotaxisP2X purinoceptor 4Homo sapiens (human)
MAPK cascadeP2X purinoceptor 7Homo sapiens (human)
cell morphogenesisP2X purinoceptor 7Homo sapiens (human)
phagolysosome assemblyP2X purinoceptor 7Homo sapiens (human)
T cell mediated cytotoxicityP2X purinoceptor 7Homo sapiens (human)
positive regulation of T cell mediated cytotoxicityP2X purinoceptor 7Homo sapiens (human)
positive regulation of protein phosphorylationP2X purinoceptor 7Homo sapiens (human)
regulation of sodium ion transportP2X purinoceptor 7Homo sapiens (human)
response to ischemiaP2X purinoceptor 7Homo sapiens (human)
membrane protein ectodomain proteolysisP2X purinoceptor 7Homo sapiens (human)
phospholipid transfer to membraneP2X purinoceptor 7Homo sapiens (human)
vesicle budding from membraneP2X purinoceptor 7Homo sapiens (human)
inflammatory responseP2X purinoceptor 7Homo sapiens (human)
mitochondrion organizationP2X purinoceptor 7Homo sapiens (human)
cell surface receptor signaling pathwayP2X purinoceptor 7Homo sapiens (human)
protein secretionP2X purinoceptor 7Homo sapiens (human)
response to xenobiotic stimulusP2X purinoceptor 7Homo sapiens (human)
response to mechanical stimulusP2X purinoceptor 7Homo sapiens (human)
response to zinc ionP2X purinoceptor 7Homo sapiens (human)
positive regulation of calcium ion transport into cytosolP2X purinoceptor 7Homo sapiens (human)
positive regulation of gene expressionP2X purinoceptor 7Homo sapiens (human)
glutamate secretionP2X purinoceptor 7Homo sapiens (human)
positive regulation of glutamate secretionP2X purinoceptor 7Homo sapiens (human)
gamma-aminobutyric acid secretionP2X purinoceptor 7Homo sapiens (human)
positive regulation of gamma-aminobutyric acid secretionP2X purinoceptor 7Homo sapiens (human)
synaptic vesicle exocytosisP2X purinoceptor 7Homo sapiens (human)
protein processingP2X purinoceptor 7Homo sapiens (human)
plasma membrane phospholipid scramblingP2X purinoceptor 7Homo sapiens (human)
sensory perception of painP2X purinoceptor 7Homo sapiens (human)
calcium-mediated signalingP2X purinoceptor 7Homo sapiens (human)
protein catabolic processP2X purinoceptor 7Homo sapiens (human)
positive regulation of bone mineralizationP2X purinoceptor 7Homo sapiens (human)
bleb assemblyP2X purinoceptor 7Homo sapiens (human)
positive regulation of prostaglandin secretionP2X purinoceptor 7Homo sapiens (human)
prostaglandin secretionP2X purinoceptor 7Homo sapiens (human)
response to lipopolysaccharideP2X purinoceptor 7Homo sapiens (human)
positive regulation of interleukin-1 alpha productionP2X purinoceptor 7Homo sapiens (human)
positive regulation of interleukin-1 beta productionP2X purinoceptor 7Homo sapiens (human)
positive regulation of interleukin-6 productionP2X purinoceptor 7Homo sapiens (human)
collagen metabolic processP2X purinoceptor 7Homo sapiens (human)
response to ATPP2X purinoceptor 7Homo sapiens (human)
response to fluid shear stressP2X purinoceptor 7Homo sapiens (human)
positive regulation of monoatomic ion transmembrane transportP2X purinoceptor 7Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 7Homo sapiens (human)
T cell proliferationP2X purinoceptor 7Homo sapiens (human)
T cell homeostasisP2X purinoceptor 7Homo sapiens (human)
NAD transportP2X purinoceptor 7Homo sapiens (human)
negative regulation of MAPK cascadeP2X purinoceptor 7Homo sapiens (human)
positive regulation of MAPK cascadeP2X purinoceptor 7Homo sapiens (human)
negative regulation of bone resorptionP2X purinoceptor 7Homo sapiens (human)
negative regulation of cell volumeP2X purinoceptor 7Homo sapiens (human)
positive regulation of glycolytic processP2X purinoceptor 7Homo sapiens (human)
ceramide biosynthetic processP2X purinoceptor 7Homo sapiens (human)
pore complex assemblyP2X purinoceptor 7Homo sapiens (human)
skeletal system morphogenesisP2X purinoceptor 7Homo sapiens (human)
homeostasis of number of cells within a tissueP2X purinoceptor 7Homo sapiens (human)
positive regulation of protein secretionP2X purinoceptor 7Homo sapiens (human)
defense response to Gram-positive bacteriumP2X purinoceptor 7Homo sapiens (human)
release of sequestered calcium ion into cytosolP2X purinoceptor 7Homo sapiens (human)
positive regulation of cytoskeleton organizationP2X purinoceptor 7Homo sapiens (human)
response to calcium ionP2X purinoceptor 7Homo sapiens (human)
response to electrical stimulusP2X purinoceptor 7Homo sapiens (human)
mitochondrial depolarizationP2X purinoceptor 7Homo sapiens (human)
membrane depolarizationP2X purinoceptor 7Homo sapiens (human)
positive regulation of mitochondrial depolarizationP2X purinoceptor 7Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 7Homo sapiens (human)
positive regulation of macrophage cytokine productionP2X purinoceptor 7Homo sapiens (human)
T cell apoptotic processP2X purinoceptor 7Homo sapiens (human)
positive regulation of T cell apoptotic processP2X purinoceptor 7Homo sapiens (human)
cellular response to ATPP2X purinoceptor 7Homo sapiens (human)
cellular response to dsRNAP2X purinoceptor 7Homo sapiens (human)
reactive oxygen species metabolic processP2X purinoceptor 7Homo sapiens (human)
apoptotic signaling pathwayP2X purinoceptor 7Homo sapiens (human)
extrinsic apoptotic signaling pathwayP2X purinoceptor 7Homo sapiens (human)
positive regulation of bleb assemblyP2X purinoceptor 7Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 7Homo sapiens (human)
response to hypoxiaP2X purinoceptor 2Homo sapiens (human)
response to ischemiaP2X purinoceptor 2Homo sapiens (human)
detection of hypoxic conditions in blood by carotid body chemoreceptor signalingP2X purinoceptor 2Homo sapiens (human)
neuromuscular synaptic transmissionP2X purinoceptor 2Homo sapiens (human)
neuromuscular junction developmentP2X purinoceptor 2Homo sapiens (human)
sensory perception of soundP2X purinoceptor 2Homo sapiens (human)
response to carbohydrateP2X purinoceptor 2Homo sapiens (human)
positive regulation of calcium ion transport into cytosolP2X purinoceptor 2Homo sapiens (human)
urinary bladder smooth muscle contractionP2X purinoceptor 2Homo sapiens (human)
peristalsisP2X purinoceptor 2Homo sapiens (human)
response to ATPP2X purinoceptor 2Homo sapiens (human)
purinergic nucleotide receptor signaling pathwayP2X purinoceptor 2Homo sapiens (human)
behavioral response to painP2X purinoceptor 2Homo sapiens (human)
skeletal muscle fiber developmentP2X purinoceptor 2Homo sapiens (human)
positive regulation of calcium-mediated signalingP2X purinoceptor 2Homo sapiens (human)
sensory perception of tasteP2X purinoceptor 2Homo sapiens (human)
excitatory postsynaptic potentialP2X purinoceptor 2Homo sapiens (human)
calcium ion transmembrane transportP2X purinoceptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (52)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
RNA bindingCaspase-7Homo sapiens (human)
aspartic-type endopeptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activityCaspase-7Homo sapiens (human)
protein bindingCaspase-7Homo sapiens (human)
peptidase activityCaspase-7Homo sapiens (human)
cysteine-type peptidase activityCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in apoptotic processCaspase-7Homo sapiens (human)
cysteine-type endopeptidase activity involved in execution phase of apoptosisCaspase-7Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
protein bindingP2Y purinoceptor 2Homo sapiens (human)
signaling receptor activityP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 2Homo sapiens (human)
A1 adenosine receptor bindingP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled UTP receptor activityP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled ADP receptor activityP2Y purinoceptor 1Homo sapiens (human)
protein bindingP2Y purinoceptor 1Homo sapiens (human)
ATP bindingP2Y purinoceptor 1Homo sapiens (human)
signaling receptor activityP2Y purinoceptor 1Homo sapiens (human)
ADP bindingP2Y purinoceptor 1Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 1Homo sapiens (human)
G protein-coupled ATP receptor activityP2Y purinoceptor 1Homo sapiens (human)
protein heterodimerization activityP2Y purinoceptor 1Homo sapiens (human)
scaffold protein bindingP2Y purinoceptor 1Homo sapiens (human)
A1 adenosine receptor bindingP2Y purinoceptor 1Homo sapiens (human)
protein bindingP2Y purinoceptor 4Homo sapiens (human)
ATP bindingP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled UTP receptor activityP2Y purinoceptor 4Homo sapiens (human)
purinergic nucleotide receptor activityP2X purinoceptor 3Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 3Homo sapiens (human)
ATP bindingP2X purinoceptor 3Homo sapiens (human)
purinergic nucleotide receptor activityP2X purinoceptor 5Homo sapiens (human)
transmembrane signaling receptor activityP2X purinoceptor 5Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 5Homo sapiens (human)
monoatomic ion channel activityP2X purinoceptor 5Homo sapiens (human)
ATP bindingP2X purinoceptor 5Homo sapiens (human)
ATP-gated ion channel activityP2X purinoceptor 5Homo sapiens (human)
ligand-gated monoatomic anion channel activityP2X purinoceptor 5Homo sapiens (human)
purinergic nucleotide receptor activityP2X purinoceptor 4Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 4Homo sapiens (human)
signaling receptor bindingP2X purinoceptor 4Homo sapiens (human)
copper ion bindingP2X purinoceptor 4Homo sapiens (human)
protein bindingP2X purinoceptor 4Homo sapiens (human)
ATP bindingP2X purinoceptor 4Homo sapiens (human)
zinc ion bindingP2X purinoceptor 4Homo sapiens (human)
identical protein bindingP2X purinoceptor 4Homo sapiens (human)
cadherin bindingP2X purinoceptor 4Homo sapiens (human)
ligand-gated calcium channel activityP2X purinoceptor 4Homo sapiens (human)
lipopolysaccharide bindingP2X purinoceptor 7Homo sapiens (human)
purinergic nucleotide receptor activityP2X purinoceptor 7Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 7Homo sapiens (human)
signaling receptor bindingP2X purinoceptor 7Homo sapiens (human)
protein bindingP2X purinoceptor 7Homo sapiens (human)
ATP bindingP2X purinoceptor 7Homo sapiens (human)
identical protein bindingP2X purinoceptor 7Homo sapiens (human)
purinergic nucleotide receptor activityP2X purinoceptor 2Homo sapiens (human)
extracellularly ATP-gated monoatomic cation channel activityP2X purinoceptor 2Homo sapiens (human)
ATP bindingP2X purinoceptor 2Homo sapiens (human)
ligand-gated monoatomic ion channel activityP2X purinoceptor 2Homo sapiens (human)
identical protein bindingP2X purinoceptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (56)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular spaceCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
cytoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
nucleusCaspase-7Homo sapiens (human)
nucleoplasmCaspase-7Homo sapiens (human)
cytosolCaspase-7Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
plasma membraneP2Y purinoceptor 2Homo sapiens (human)
plasma membraneP2Y purinoceptor 2Homo sapiens (human)
plasma membraneP2Y purinoceptor 1Homo sapiens (human)
ciliumP2Y purinoceptor 1Homo sapiens (human)
cell surfaceP2Y purinoceptor 1Homo sapiens (human)
postsynaptic densityP2Y purinoceptor 1Homo sapiens (human)
basolateral plasma membraneP2Y purinoceptor 1Homo sapiens (human)
apical plasma membraneP2Y purinoceptor 1Homo sapiens (human)
dendriteP2Y purinoceptor 1Homo sapiens (human)
cell bodyP2Y purinoceptor 1Homo sapiens (human)
postsynaptic membraneP2Y purinoceptor 1Homo sapiens (human)
presynaptic active zone membraneP2Y purinoceptor 1Homo sapiens (human)
glutamatergic synapseP2Y purinoceptor 1Homo sapiens (human)
plasma membraneP2Y purinoceptor 1Homo sapiens (human)
plasma membraneP2Y purinoceptor 4Homo sapiens (human)
basolateral plasma membraneP2Y purinoceptor 4Homo sapiens (human)
apical plasma membraneP2Y purinoceptor 4Homo sapiens (human)
presynaptic active zone membraneP2Y purinoceptor 4Homo sapiens (human)
glutamatergic synapseP2Y purinoceptor 4Homo sapiens (human)
plasma membraneP2Y purinoceptor 4Homo sapiens (human)
plasma membraneP2X purinoceptor 3Homo sapiens (human)
axonP2X purinoceptor 3Homo sapiens (human)
Schaffer collateral - CA1 synapseP2X purinoceptor 3Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseP2X purinoceptor 3Homo sapiens (human)
postsynapseP2X purinoceptor 3Homo sapiens (human)
receptor complexP2X purinoceptor 3Homo sapiens (human)
plasma membraneP2X purinoceptor 3Homo sapiens (human)
plasma membraneP2X purinoceptor 7Rattus norvegicus (Norway rat)
cytosolP2X purinoceptor 5Homo sapiens (human)
plasma membraneP2X purinoceptor 5Homo sapiens (human)
postsynapseP2X purinoceptor 5Homo sapiens (human)
plasma membraneP2X purinoceptor 5Homo sapiens (human)
lysosomal membraneP2X purinoceptor 4Homo sapiens (human)
plasma membraneP2X purinoceptor 4Homo sapiens (human)
membraneP2X purinoceptor 4Homo sapiens (human)
cell junctionP2X purinoceptor 4Homo sapiens (human)
neuronal cell bodyP2X purinoceptor 4Homo sapiens (human)
terminal boutonP2X purinoceptor 4Homo sapiens (human)
dendritic spineP2X purinoceptor 4Homo sapiens (human)
cell bodyP2X purinoceptor 4Homo sapiens (human)
perinuclear region of cytoplasmP2X purinoceptor 4Homo sapiens (human)
extracellular exosomeP2X purinoceptor 4Homo sapiens (human)
plasma membraneP2X purinoceptor 4Homo sapiens (human)
cytoplasmP2X purinoceptor 7Homo sapiens (human)
mitochondrionP2X purinoceptor 7Homo sapiens (human)
plasma membraneP2X purinoceptor 7Homo sapiens (human)
cell-cell junctionP2X purinoceptor 7Homo sapiens (human)
external side of plasma membraneP2X purinoceptor 7Homo sapiens (human)
membraneP2X purinoceptor 7Homo sapiens (human)
neuromuscular junctionP2X purinoceptor 7Homo sapiens (human)
blebP2X purinoceptor 7Homo sapiens (human)
neuronal cell bodyP2X purinoceptor 7Homo sapiens (human)
presynapseP2X purinoceptor 7Homo sapiens (human)
postsynapseP2X purinoceptor 7Homo sapiens (human)
plasma membraneP2X purinoceptor 7Homo sapiens (human)
plasma membraneP2X purinoceptor 2Homo sapiens (human)
apical plasma membraneP2X purinoceptor 2Homo sapiens (human)
neuronal cell bodyP2X purinoceptor 2Homo sapiens (human)
postsynapseP2X purinoceptor 2Homo sapiens (human)
neuronal dense core vesicleP2X purinoceptor 2Homo sapiens (human)
receptor complexP2X purinoceptor 2Homo sapiens (human)
plasma membraneP2X purinoceptor 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (76)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346426Human P2Y6 receptor (P2Y receptors)2016Neuropharmacology, 05, Volume: 104Pharmacology and structure of P2Y receptors.
AID1346309Human P2Y1 receptor (P2Y receptors)2002Molecular pharmacology, Nov, Volume: 62, Issue:5
Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist.
AID1346305Human P2Y13 receptor (P2Y receptors)2003Molecular pharmacology, Jul, Volume: 64, Issue:1
Pharmacological characterization of the human P2Y13 receptor.
AID1346348Human P2Y4 receptor (P2Y receptors)2009Purinergic signalling, Mar, Volume: 5, Issue:1
Development of selective agonists and antagonists of P2Y receptors.
AID165064Compound was tested in a functional ion channel assay of ATP-induced current at recombinant rat P2X1 receptor expressed in Xenopus oocytes.1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors.
AID1884357Antagonist activity against human P2X4R stably transfected in human 1321N1 cells incubated for 30 mins by Fura-2 AM staining based calcium influx assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Therapeutic potentials and structure-activity relationship of 1,3-benzodioxole N-carbamothioyl carboxamide derivatives as selective and potent antagonists of P2X4 and P2X7 receptors.
AID1059229Antagonist activity at human P2X3 receptor2013European journal of medicinal chemistry, , Volume: 70Design and synthesis of potent and selective P2X₃ receptor antagonists derived from PPADS as potential pain modulators.
AID150307Inhibition of inward ion current elicited by ATP at human P2X4 receptor (mutant type)2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
AID150178The compound was evaluated for antagonist activity against recombinant rat P2X purinoceptor 7 (P2X7)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150311Inhibition of inward ion current elicited by ATP at rat P2X6 receptor (mutant type)2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
AID165065Compound was tested in a functional ion channel assay of ATP-induced current at recombinant rat P2X3 receptor expressed in Xenopus oocytes.1998Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13
A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors.
AID150310Inhibition of inward ion current elicited by ATP at rat P2X4 receptor (wild type)2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
AID150312Inhibition of inward ion current elicited by ATP at rat P2X6 receptor (wild type)2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
AID1415794Inhibition of NPP1 in Wistar rat C6 cells using [gamma-32P]ATP as substrate pretreated for 30 mins followed by substrate addition and measured after 90 mins by TLC analysis2017MedChemComm, May-01, Volume: 8, Issue:5
Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors.
AID150172Antagonist activity against recombinant rat P2X purinoceptor 6 (P2X6 )2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID1059221Antagonist activity at recombinant human P2X7 receptor assessed as inhibition of BzATP-mediated Yo-Pro uptake measured for 1 hr by FLIPR assay2013European journal of medicinal chemistry, , Volume: 70Design and synthesis of potent and selective P2X₃ receptor antagonists derived from PPADS as potential pain modulators.
AID1884362Antagonist activity against human P2X7R stably transfected in human 1321N1 cells at 50 uM incubated for 30 mins by Fura-2 AM staining based calcium influx assay relative to control2022European journal of medicinal chemistry, Aug-05, Volume: 238Therapeutic potentials and structure-activity relationship of 1,3-benzodioxole N-carbamothioyl carboxamide derivatives as selective and potent antagonists of P2X4 and P2X7 receptors.
AID152481The compound was evaluated for antagonist activity against recombinant rat P2X purinoceptor 1 (P2X1) at 1 uM, expressed in Xenopus oocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150156The compound was evaluated for antagonist activity against recombinant rat P2X purinoceptor 3 (P2X3) at 10 uM, expressed in Xenopus oocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID1884355Antagonist activity against human P2X2R stably transfected in human 1321N1 cells incubated for 30 mins by Fura-2 AM staining based calcium influx assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Therapeutic potentials and structure-activity relationship of 1,3-benzodioxole N-carbamothioyl carboxamide derivatives as selective and potent antagonists of P2X4 and P2X7 receptors.
AID150638The compound was evaluated for agonist activity against phospholipase C coupled recombinant human P2Y purinoceptor 6 (P2Y6)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150464Evaluated for agonist activity against phospholipase C coupled P2Y purinoceptor 1 (P2Y1) of rat erythrocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID1654778Antagonist activity at rat P2X1 receptor2020Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11
Discovery and Structure Relationships of Salicylanilide Derivatives as Potent, Non-acidic P2X1 Receptor Antagonists.
AID150305Inhibition of inward ion current elicited by ATP was determined at recombinant P2X3 receptor expressed in Xenopus oocytes2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
AID1884352Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 50 uM after 24 hrs by MTT assay relative to control2022European journal of medicinal chemistry, Aug-05, Volume: 238Therapeutic potentials and structure-activity relationship of 1,3-benzodioxole N-carbamothioyl carboxamide derivatives as selective and potent antagonists of P2X4 and P2X7 receptors.
AID1884359Antagonist activity against human P2X5R stably transfected in human 1321N1 cells incubated for 30 mins by Fura-2 AM staining based calcium influx assay2022European journal of medicinal chemistry, Aug-05, Volume: 238Therapeutic potentials and structure-activity relationship of 1,3-benzodioxole N-carbamothioyl carboxamide derivatives as selective and potent antagonists of P2X4 and P2X7 receptors.
AID150303Inhibition of inward ion current elicited by ATP at P2X2 receptor expressed in Xenopus oocytes2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
AID150170Antagonist activity against recombinant rat P2X purinoceptor 5 (P2X5)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150331Evaluated for agonist activity against phospholipase C coupled P2Y purinoceptor 1 (P2Y1) of human erythrocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID1059230Antagonist activity at mouse P2X1 receptor2013European journal of medicinal chemistry, , Volume: 70Design and synthesis of potent and selective P2X₃ receptor antagonists derived from PPADS as potential pain modulators.
AID150165Antagonist activity against recombinant rat P2X purinoceptor 4 (P2X4) at 3 uM, expressed in Xenopus oocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150644Inhibition of 10 nM 2-MeS-ADP-stimulated phospholipase C in turkey erythrocyte membranes using [3H]inositol2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
AID150300Inhibition of inward ion current elicited by ATP at P2X1 receptor expressed in Xenopus oocytes2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
AID1884354Cytotoxicity against HEK293 cells assessed as reduction in cell viability at 50 uM after 24 hrs by MTT assay relative to control2022European journal of medicinal chemistry, Aug-05, Volume: 238Therapeutic potentials and structure-activity relationship of 1,3-benzodioxole N-carbamothioyl carboxamide derivatives as selective and potent antagonists of P2X4 and P2X7 receptors.
AID150145The compound was evaluated for antagonist activity against recombinant rat receptor P2X purinoceptor 2 (P2X2) at 30 uM, expressed in Xenopus oocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID1884353Cytotoxicity against human 1321N1 cells assessed as reduction in cell viability at 50 uM after 24 hrs by MTT assay relative to control2022European journal of medicinal chemistry, Aug-05, Volume: 238Therapeutic potentials and structure-activity relationship of 1,3-benzodioxole N-carbamothioyl carboxamide derivatives as selective and potent antagonists of P2X4 and P2X7 receptors.
AID150627The compound was evaluated for antagonist activity against phospholipase C coupled recombinant human P2Y purinoceptor 4 (P2Y4)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150161Antagonist activity against recombinant human P2X purinoceptor 4 (P2X4)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150309Inhibition of inward ion current elicited by ATP at rat P2X4 receptor (mutant type)2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
AID150308Inhibition of inward ion current elicited by ATP at mouse P2X4 receptor (mutant type)2001Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3
Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.
AID150151Antagonist activity against recombinant human P2X purinoceptor 3 (P2X3 )2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150321Evaluated for agonist activity against phospholipase C coupled recombinant human P2Y purinoceptor 2 (P2Y2)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150495Antagonist activity against phospholipase C coupled rat P2Y purinoceptor 12 (P2Y12)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (600)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's126 (21.00)18.2507
2000's355 (59.17)29.6817
2010's108 (18.00)24.3611
2020's11 (1.83)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews7 (1.17%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
Other591 (98.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
phaclofen[no description available]low00organophosphate oxoanion;
zwitterion
glycinamide ribonucleotide[no description available]low00organophosphate oxoanion
cyclic amp[no description available]low00organophosphate oxoanionhuman metabolite;
Saccharomyces cerevisiae metabolite
adenosine thiamine triphosphate[no description available]low00organophosphate oxoanion
thiamine pyrophosphate[no description available]low00organophosphate oxoanion;
vitamin B1		human metabolite;
Saccharomyces cerevisiae metabolite
nad[no description available]low00organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
xylitol 5-phosphate[no description available]low00organophosphate oxoanion
1-phospho-5-s-methylthioribulose[no description available]low00organophosphate oxoanionhuman metabolite;
Saccharomyces cerevisiae metabolite
ticrynafen[no description available]low00monocarboxylic acid anion;
organophosphate oxoanion		human metabolite
cytidine diphosphate choline[no description available]low00organophosphate oxoanion
diglycerol phosphate[no description available]low00organophosphate oxoanion
diadenosine tetraphosphate[no description available]low00organophosphate oxoanionhuman metabolite;
Saccharomyces cerevisiae metabolite
lipid iii[no description available]low00carbohydrate acid derivative anion;
monocarboxylic acid anion;
organophosphate oxoanion
p(1),p(5)-di(adenosine-5'-)pentaphosphate[no description available]low00organophosphate oxoanion
nicotinate mononucleotide[no description available]low00organophosphate oxoanionhuman metabolite;
Saccharomyces cerevisiae metabolite
6-phosphogluconolactone[no description available]low00organophosphate oxoanionhuman metabolite;
Saccharomyces cerevisiae metabolite
7-methylguanosine-5'-monophosphate[no description available]low00organophosphate oxoanion
molybdenum cofactor[no description available]low00Mo-molybdopterin cofactor;
organophosphate oxoanion
bis(molybdopterin guanine dinucleotide)molybdenum[no description available]low00organophosphate oxoanion
3'-deoxy-3',4'-didehydro-CTP(4-)[no description available]low00organophosphate oxoanion
mrs 2219[no description available]medium30
mrs2159[no description available]medium20
pyridoxal phosphate[no description available]medium5860methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate		coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
suramin[no description available]medium2100naphthalenesulfonic acid;
phenylureas;
secondary carboxamide		angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug
adenosine diphosphate[no description available]medium660adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
uridine diphosphate[no description available]medium150pyrimidine ribonucleoside 5'-diphosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
mouse metabolite
uridine triphosphate[no description available]medium620pyrimidine ribonucleoside 5'-triphosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
mouse metabolite
trypan blue[no description available]medium10
2'-deoxyadenosine triphosphate[no description available]medium102'-deoxyadenosine 5'-phosphate;
purine 2'-deoxyribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite
diadenosine tetraphosphate[no description available]medium100diadenosyl tetraphosphateEscherichia coli metabolite;
mouse metabolite
5'-adenylyl (beta,gamma-methylene)diphosphonate[no description available]medium100nucleoside triphosphate analogue
alpha,beta-methyleneadenosine 5'-triphosphate[no description available]medium1330nucleoside triphosphate analogue
methylthio-adp[no description available]medium80
adenosine 5'-o-(3-thiotriphosphate)[no description available]medium200nucleoside triphosphate analogue
ar c67085mx[no description available]medium10
2-methylthio-atp[no description available]medium460
adp beta s[no description available]medium190
kn 62[no description available]medium110piperazines
nf023[no description available]medium10
cangrelor[no description available]medium30adenosine 5'-phosphate;
aryl sulfide;
nucleoside triphosphate analogue;
organochlorine compound;
organofluorine compound;
secondary amino compound		P2Y12 receptor antagonist;
platelet aggregation inhibitor
acid blue 129[no description available]medium10
mrs 2179[no description available]medium10
2-methylthioadenosine 5'-monophosphate[no description available]medium10
Reactive blue 2[no description available]medium20anthraquinone
diadenosine tetraphosphate[no description available]medium10organophosphate oxoanionhuman metabolite;
Saccharomyces cerevisiae metabolite
pregabalin[no description available]medium10gamma-amino acidanticonvulsant;
calcium channel blocker
a-317491[no description available]medium70
adenosine 5'-methylenediphosphate[no description available]medium20nucleoside diphosphate analogue
3'-o-(4-benzoyl)benzoyladenosine 5'-triphosphate[no description available]medium210purine ribonucleoside triphosphate
adenosine 5'-diphosphate 2',3'-dialdehyde[no description available]medium10
arl-67156[no description available]medium80
arylid[no description available]medium10
imd 0354[no description available]medium10benzamides
nf 449[no description available]medium10
piperonylic acid[no description available]medium10aromatic carboxylic acid;
benzodioxoles;
monocarboxylic acid		antifungal agent;
EC 1.14.14.91 ( trans-cinnamate 4-monooxygenase) inhibitor;
plant metabolite;
vulnerary
c.i. 42510[no description available]medium90
coomassie brilliant blue[no description available]medium90
prazosin[no description available]medium100aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
propranolol[no description available]medium30naphthalenes;
propanolamine;
secondary amine		anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic
choline[no description available]medium30cholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite
fluorexon[no description available]medium10xanthene dyefluorochrome
erythrosine[no description available]medium10
4-o-methyl-phorbol-12,13-didecanoate[no description available]medium10
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid[no description available]medium70
fg 9041[no description available]medium10quinoxaline derivative
lanthanum[no description available]medium20f-block element atom;
lanthanoid atom;
scandium group element atom
lanthanum chloride[no description available]medium10
gadolinium chloride[no description available]medium20gadolinium coordination entityTRP channel blocker
gadolinium[no description available]medium50f-block element atom;
lanthanoid atom
2-amino-5-phosphonovalerate[no description available]medium70non-proteinogenic alpha-amino acidNMDA receptor antagonist
bicuculline[no description available]medium40benzylisoquinoline alkaloid;
isoquinoline alkaloid;
isoquinolines		agrochemical;
central nervous system stimulant;
GABA-gated chloride channel antagonist;
GABAA receptor antagonist;
neurotoxin
probenecid[no description available]medium20benzoic acids;
sulfonamide		uricosuric drug
strychnine[no description available]medium40monoterpenoid indole alkaloid;
organic heteroheptacyclic compound		avicide;
cholinergic antagonist;
glycine receptor antagonist;
neurotransmitter agent;
rodenticide
valine[no description available]medium20L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
quinoxalines[no description available]medium30mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene
fluorocitrate[no description available]medium20carbonyl compound
paroxetine[no description available]medium10aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines		antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor
allyl isothiocyanate[no description available]medium10alkenyl isothiocyanate;
isothiocyanate		antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
lachrymator;
metabolite
tetrodotoxin[no description available]medium250azatetracycloalkane;
oxatetracycloalkane;
quinazoline alkaloid		animal metabolite;
bacterial metabolite;
marine metabolite;
neurotoxin;
voltage-gated sodium channel blocker
atropine[no description available]medium190
capsaicin[no description available]medium220capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
hexamethonium[no description available]medium70quaternary ammonium salt
thiourea[no description available]medium30one-carbon compound;
thioureas;
ureas		antioxidant;
chromophore
hydroxyl radical[no description available]medium10oxygen hydride;
oxygen radical;
reactive oxygen species
1,3-dimethylthiourea[no description available]medium10
capsazepine[no description available]medium40benzazepine;
catechols;
monochlorobenzenes;
thioureas		capsaicin receptor antagonist
yo-pro 1[no description available]medium60
benzoxazoles[no description available]medium601,3-benzoxazoles;
mancude organic heterobicyclic parent
arginine[no description available]medium20arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
2-(2-(5-bromo-1h-indol-3-yl)ethyl)-3-(1-methylethoxyphenyl)-4-(3h)-quinazolinone[no description available]medium10quinazolines
8-phenyltheophylline[no description available]medium60
theophylline[no description available]medium220dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
triazoles[no description available]medium701,2,3-triazole
2',3'-o-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate[no description available]medium300C-nitro compound;
spiroketal		antagonist
framycetin[no description available]medium10aminoglycosideallergen;
antibacterial drug;
Escherichia coli metabolite
n-methylglutamate[no description available]medium10methyl-L-glutamic acid;
N-methyl-L-alpha-amino acid		bacterial xenobiotic metabolite
phentolamine[no description available]medium80imidazoles;
phenols;
substituted aniline;
tertiary amino compound		alpha-adrenergic antagonist;
vasodilator agent
2-aminoethoxydiphenyl borate[no description available]medium40organoboron compound;
primary amino compound		calcium channel blocker;
IP3 receptor antagonist;
potassium channel opener
niflumic acid[no description available]medium10aromatic carboxylic acid;
pyridines
nifedipine[no description available]medium60C-nitro compound;
dihydropyridine;
methyl ester		calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent
ethidium[no description available]medium40phenanthridinesfluorochrome;
intercalator
carbenoxolone sodium[no description available]medium60triterpenoid
ng-nitroarginine methyl ester[no description available]medium180alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
dizocilpine maleate[no description available]medium40maleate salt;
tetracyclic antidepressant		anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist
nicotine[no description available]medium403-(1-methylpyrrolidin-2-yl)pyridineanxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic
l-161982[no description available]medium10biphenyls
thiophenes[no description available]medium10mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
p(1),p(5)-di(adenosine-5'-)pentaphosphate[no description available]medium120organophosphate oxoanion
glutamic acid[no description available]medium270glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
transforming growth factor beta[no description available]medium20
bafilomycin a1[no description available]medium10cyclic hemiketal;
macrolide antibiotic;
oxanes		apoptosis inducer;
autophagy inhibitor;
bacterial metabolite;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
ferroptosis inhibitor;
fungicide;
potassium ionophore;
toxin
lactic acid[no description available]medium102-hydroxy monocarboxylic acidalgal metabolite;
Daphnia magna metabolite
amiloride[no description available]medium30aromatic amine;
guanidines;
organochlorine compound;
pyrazines		diuretic;
sodium channel blocker
kb r7943[no description available]medium20
calcimycin[no description available]medium10benzoxazole
calciseptine[no description available]medium10
5-nitro-2-(3-phenylpropylamino)benzoic acid[no description available]medium10nitrobenzoic acid
staurosporine[no description available]medium10ammonium ion derivative
4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid[no description available]medium10stilbenoid
chlorine[no description available]medium50halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite
gamma-aminobutyric acid[no description available]medium90amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid		human metabolite;
neurotransmitter;
Saccharomyces cerevisiae metabolite;
signalling molecule
sr 95531[no description available]medium10methoxybenzenes
sb 203580[no description available]medium20imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide		EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent
1-(5-isoquinolinesulfonyl)-2-methylpiperazine[no description available]medium100isoquinolines;
N-sulfonylpiperazine		EC 2.7.11.13 (protein kinase C) inhibitor
glycine[no description available]medium70alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
gw791343[no description available]medium20
dinoprostone[no description available]medium40prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
tetradecanoylphorbol acetate[no description available]medium20acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator
colforsin[no description available]medium40acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol		adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist
n-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide[no description available]medium10
15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid[no description available]medium20
sk&f-96356[no description available]medium10
u 73122[no description available]medium90aromatic ether;
aza-steroid;
maleimides		EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor
hydrogen carbonate[no description available]medium20carbon oxoanioncofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
wortmannin[no description available]medium20acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound		anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent
pd 98059[no description available]medium10aromatic amine;
monomethoxyflavone		EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector
neuropeptide y[no description available]medium30
u 69593[no description available]medium10monocarboxylic acid amide;
N-alkylpyrrolidine;
organic heterobicyclic compound;
oxaspiro compound		anti-inflammatory agent;
diuretic;
kappa-opioid receptor agonist
naloxone[no description available]medium20morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol		antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist
morphine[no description available]medium10morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound		anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic
enkephalin, ala(2)-mephe(4)-gly(5)-[no description available]medium10
1,3-dipropyl-8-cyclopentylxanthine[no description available]medium180oxopurineadenosine A1 receptor antagonist;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
adenosine[no description available]medium290adenosines;
purines D-ribonucleoside		analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent
8-(4-sulfophenyl)theophylline[no description available]medium90
egtazic acid[no description available]medium90diether;
tertiary amino compound;
tetracarboxylic acid		chelator
tubocurarine[no description available]medium30bisbenzylisoquinoline alkaloiddrug allergen;
muscle relaxant;
nicotinic antagonist
fm1 43[no description available]medium10organic bromide salt;
pyridinium salt;
quaternary ammonium salt;
tertiary amine		fluorochrome
diisopropylamine dichloroacetate[no description available]medium10carboxylic acid;
organohalogen compound
fura-2[no description available]medium90
aspartic acid[no description available]medium20aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine[no description available]medium10N-substituted diamine;
pyridines;
tertiary amino compound		apoptosis inducer;
chelator;
copper chelator
fura-2-am[no description available]medium30
8-cyclopentyl-1,3-dimethylxanthine[no description available]medium60oxopurine
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one[no description available]medium10chromones;
morpholines;
organochlorine compound		autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector
sr 142801[no description available]medium30
piperidines[no description available]medium40
sr 140333[no description available]medium10
quinuclidines[no description available]medium30quinuclidines;
saturated organic heterobicyclic parent
verapamil[no description available]medium20aromatic ether;
nitrile;
polyether;
tertiary amino compound
dextrothyroxine[no description available]medium40
1-(2-(3-(4-methoxyphenyl)propoxy)-4-methoxyphenylethyl)-1h-imidazole[no description available]medium20ether;
imidazoles;
monomethoxybenzene		TRP channel blocker
ryanodine[no description available]medium20
caffeine[no description available]medium70purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
xanthenes[no description available]medium40xanthene
ketanserin[no description available]medium10aromatic ketone;
organofluorine compound;
piperidines;
quinazolines		alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
ondansetron[no description available]medium30carbazoles
apyrase[no description available]medium170
2',3'-dialdehyde atp[no description available]medium80
mocetinostat[no description available]medium10aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent
acetylcysteine[no description available]medium10acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
indomethacin[no description available]medium90aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
nickel sulfate[no description available]medium10metal sulfateallergen
nickel[no description available]medium20metal allergen;
nickel group element atom		epitope;
micronutrient
bibp 3226[no description available]medium10
serine[no description available]medium20L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid;
serine zwitterion;
serine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
sildenafil citrate[no description available]medium10citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent
phenylephrine[no description available]medium50phenols;
phenylethanolamines;
secondary amino compound		alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent
diinosine pentaphosphate[no description available]medium40
n(6)-cyclopentyladenosine[no description available]medium10
bromodeoxyuridine[no description available]medium20pyrimidine 2'-deoxyribonucleosideantimetabolite;
antineoplastic agent
1,2-bis(2-aminophenoxy)ethane n,n,n',n'-tetraacetic acid acetoxymethyl ester[no description available]medium10
meclofenamic acid[no description available]medium30aminobenzoic acid;
organochlorine compound;
secondary amino compound		analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug
glyburide[no description available]medium30monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent
ritanserin[no description available]medium10organofluorine compound;
piperidines;
thiazolopyrimidine		antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist
tropisetron[no description available]medium20indolyl carboxylic acid
carbachol[no description available]medium120ammonium salt;
carbamate ester		cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic
afdx 116[no description available]medium10benzodiazepine
tolterodine tartrate[no description available]medium10tartrate salt
solifenacin succinate[no description available]medium10isoquinolines
oxybutynin[no description available]medium20acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound		antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic
pirenzepine[no description available]medium10pyridobenzodiazepineanti-ulcer drug;
antispasmodic drug;
muscarinic antagonist
hydrochloric acid[no description available]medium10chlorine molecular entity;
gas molecular entity;
hydrogen halide;
mononuclear parent hydride		mouse metabolite
phenylpropanolamine[no description available]medium10amphetamines;
phenethylamine alkaloid		plant metabolite
darifenacin[no description available]medium101-benzofurans;
monocarboxylic acid amide;
pyrrolidines		antispasmodic drug;
muscarinic antagonist
n-methylscopolamine[no description available]medium10
benzofurans[no description available]medium20
organophosphonates[no description available]medium10divalent inorganic anion;
phosphite ion
barium[no description available]medium30alkaline earth metal atom;
elemental barium
desipramine[no description available]medium10dibenzoazepine;
secondary amino compound		adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor
granisetron[no description available]medium30aromatic amide;
indazoles
bumetanide[no description available]medium10amino acid;
benzoic acids;
sulfonamide		diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
sb 204070a[no description available]medium10
sucrose[no description available]medium10glycosyl glycosidealgal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent
kynurenic acid[no description available]medium70monohydroxyquinoline;
quinolinemonocarboxylic acid		G-protein-coupled receptor agonist;
human metabolite;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist;
Saccharomyces cerevisiae metabolite
methylatropine[no description available]medium20
deoxyglucose[no description available]medium10
lignans[no description available]medium10
cyclic gmp[no description available]medium303',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
schizandrin[no description available]medium10
melitten[no description available]medium20
mecamylamine[no description available]medium20primary aliphatic amine
wb 4101[no description available]medium10aromatic ether;
benzodioxine;
secondary amino compound		alpha-adrenergic antagonist
abscisic acid[no description available]medium102-trans-abscisic acid
fluo-3[no description available]medium30xanthene dyefluorochrome
substance p[no description available]medium30peptideneurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent
cadmium[no description available]medium60cadmium molecular entity;
zinc group element atom
l 703606[no description available]medium10
arginine vasopressin[no description available]medium20vasopressincardiovascular drug;
hematologic agent;
mitogen
oxytocin[no description available]medium30heterodetic cyclic peptide;
peptide hormone		oxytocic;
vasodilator agent
cobalt[no description available]medium10cobalt group element atom;
metal allergen		micronutrient
quinacrine[no description available]medium10acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
cytidine triphosphate[no description available]medium20cytidine 5'-phosphate;
pyrimidine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite
ethylmaleimide[no description available]medium10maleimidesanticoronaviral agent;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.1.1 (hexokinase) inhibitor
methoxamine[no description available]medium20amphetaminesalpha-adrenergic agonist;
antihypotensive agent
tyrosine[no description available]medium20amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
staurosporine aglycone[no description available]medium10
2-chloroadenosine[no description available]medium20purine nucleoside
carbon monoxide[no description available]medium10carbon oxide;
gas molecular entity;
one-carbon compound		biomarker;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
human metabolite;
ligand;
metabolite;
mitochondrial respiratory-chain inhibitor;
mouse metabolite;
neurotoxin;
neurotransmitter;
P450 inhibitor;
probe;
signalling molecule;
vasodilator agent
angiotensin ii[no description available]medium30amino acid zwitterion;
angiotensin II		human metabolite
fura red[no description available]medium10
fluorescein-5-isothiocyanate[no description available]medium40fluorescein isothiocyanate
adenosine monophosphate[no description available]medium100adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
inositol 1,4,5-trisphosphate[no description available]medium50myo-inositol trisphosphatemouse metabolite
guanosine triphosphate[no description available]medium60guanosine 5'-phosphate;
purine ribonucleoside 5'-triphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
thapsigargin[no description available]medium70butyrate ester;
organic heterotricyclic compound;
sesquiterpene lactone		calcium channel blocker;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
6-cyano-7-nitroquinoxaline-2,3-dione[no description available]medium110quinoxaline derivative
dextroamphetamine[no description available]medium101-phenylpropan-2-amineadrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent
potassium chloride[no description available]medium60inorganic chloride;
inorganic potassium salt;
potassium salt		fertilizer
omega-n-methylarginine[no description available]medium10amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid
carbocyanines[no description available]medium10cyanine dye;
organic iodide salt		fluorochrome
methane[no description available]medium10alkane;
gas molecular entity;
mononuclear parent hydride;
one-carbon compound		bacterial metabolite;
fossil fuel;
greenhouse gas
8-bromocyclic gmp[no description available]medium103',5'-cyclic purine nucleotide;
organobromine compound		muscle relaxant;
protein kinase G agonist
cytochalasin d[no description available]medium20
Brilliant Blue[no description available]medium20organic molecular entity
1,2-bis(2-aminophenoxy)ethane-n,n,n',n'-tetraacetic acid[no description available]medium40polyamino carboxylic acid;
tetracarboxylic acid		chelator
guanosine 5'-o-(2-thiodiphosphate)[no description available]medium10nucleoside diphosphate analogue
guanosine diphosphate[no description available]medium10guanosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		Escherichia coli metabolite;
mouse metabolite;
uncoupling protein inhibitor
jasplakinolide[no description available]medium10cyclodepsipeptide;
phenols		actin polymerisation inducer;
animal metabolite;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
neuroprotective agent
guanosine 5'-o-(3-thiotriphosphate)[no description available]medium10nucleoside triphosphate analogue
benzamil[no description available]medium10guanidines;
pyrazines
memantine[no description available]medium10adamantanes;
primary aliphatic amine		antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist
nitroarginine[no description available]medium70guanidines;
L-arginine derivative;
N-nitro compound;
non-proteinogenic L-alpha-amino acid
nf 279[no description available]medium10
2,2'-(hydroxynitrosohydrazono)bis-ethanamine[no description available]medium10
vasoactive intestinal peptide[no description available]medium70
vasoactive intestinal peptide (10-28)[no description available]medium10
proline[no description available]medium10amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid		algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
leucine[no description available]medium10amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
isoflurane[no description available]medium20organofluorine compoundinhalation anaesthetic
sevoflurane[no description available]medium30ether;
organofluorine compound		central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor
3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid[no description available]medium20
sulpiride[no description available]medium10benzamides;
N-alkylpyrrolidine;
sulfonamide		antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist
quinpirole[no description available]medium10pyrazoloquinolinedopamine agonist
cresyl violet[no description available]medium10
histidine[no description available]medium20amino acid zwitterion;
histidine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
sq-23377[no description available]medium30cyclic ether;
enol;
polyunsaturated fatty acid;
very long-chain fatty acid		calcium ionophore;
metabolite
clotrimazole[no description available]medium10conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes		antiinfective agent;
environmental contaminant;
xenobiotic
gallic acid[no description available]medium10trihydroxybenzoic acidantineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite
8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate[no description available]medium10trihydroxybenzoic acid
bis(1,3-dibutylbarbiturate)trimethine oxonol[no description available]medium10
isoxazoles[no description available]medium10isoxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
oxidopamine[no description available]medium20benzenetriol;
catecholamine;
primary amino compound		drug metabolite;
human metabolite;
neurotoxin
2-(4-(2-carboxyethyl)phenethylamino)-5'-n-ethylcarboxamidoadenosine[no description available]medium10adenosines;
dicarboxylic acid monoamide;
monocarboxylic acid		adenosine A2A receptor agonist;
anti-inflammatory agent
4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone[no description available]medium10methoxybenzenes
lidocaine[no description available]medium20benzenes;
monocarboxylic acid amide;
tertiary amino compound		anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic
qx-314[no description available]medium10monocarboxylic acid amidelocal anaesthetic
quinazolines[no description available]medium20azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
cgs 15943[no description available]medium10aromatic amine;
biaryl;
furans;
organochlorine compound;
primary amino compound;
quinazolines;
triazoloquinazoline		adenosine A1 receptor antagonist;
adenosine A2A receptor antagonist;
antineoplastic agent;
central nervous system stimulant
brefeldin a[no description available]medium20macrolide antibioticPenicillium metabolite
phorbol 12,13-dibutyrate[no description available]medium10butyrate ester;
phorbol ester;
tertiary alpha-hydroxy ketone
chelerythrine[no description available]medium20benzophenanthridine alkaloid;
organic cation		antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor
furosemide[no description available]medium20chlorobenzoic acid;
furans;
sulfonamide		environmental contaminant;
loop diuretic;
xenobiotic
h 89[no description available]medium10N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
picrotoxin[no description available]medium40
idazoxan[no description available]medium20benzodioxine;
imidazolines		alpha-adrenergic antagonist
estriol[no description available]medium1016alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid		estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite
iberiotoxin[no description available]medium10
estriol succinate[no description available]medium10hemisuccinate;
steroid ester
nan 190[no description available]medium10N-alkylpiperazine;
N-arylpiperazine;
phthalimides		serotonergic antagonist
n-methylaspartate[no description available]medium40amino dicarboxylic acid;
D-alpha-amino acid;
D-aspartic acid derivative;
secondary amino compound		neurotransmitter agent
uridine[no description available]medium10uridinesdrug metabolite;
fundamental metabolite;
human metabolite
y 27632[no description available]medium10aromatic amide
ml 9[no description available]medium10
glucagon[no description available]medium10peptide hormone
proadifen[no description available]medium10diarylmethane
salicylates[no description available]medium10monohydroxybenzoateplant metabolite
adenylyl imidodiphosphate[no description available]medium20adenosine 5'-phosphate
zm 241385[no description available]medium20diamino-1,3,5-triazine
thiazolyl blue[no description available]medium10organic bromide saltcolorimetric reagent;
dye
thiazoles[no description available]medium101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
desoxycorticosterone[no description available]medium1020-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
yohimbine[no description available]medium40methyl 17-hydroxy-20xi-yohimban-16-carboxylatealpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist
muscimol[no description available]medium10alkaloid;
isoxazoles;
primary amino compound		fungal metabolite;
GABA agonist;
oneirogen;
psychotropic drug
citric acid, anhydrous[no description available]medium10tricarboxylic acidantimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite
interleukin-8[no description available]medium10
baclofen[no description available]medium10amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound		central nervous system depressant;
GABA agonist;
muscle relaxant
isoguvacine[no description available]medium10tetrahydropyridine
arachidonic acid[no description available]medium40icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite
histamine[no description available]medium50aralkylamino compound;
imidazoles		human metabolite;
mouse metabolite;
neurotransmitter
nitroglycerin[no description available]medium20nitroglycerolexplosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic
2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide[no description available]medium10
oxadiazoles[no description available]medium20
1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one[no description available]medium20oxadiazoloquinoxalineEC 4.6.1.2 (guanylate cyclase) inhibitor
u 0126[no description available]medium10aryl sulfide;
dinitrile;
enamine;
substituted aniline		antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent
dapi[no description available]medium10indolesfluorochrome
manganese[no description available]medium20elemental manganese;
manganese group element atom		Escherichia coli metabolite;
micronutrient
thiorphan[no description available]medium10N-acyl-amino acid
ciproxifan[no description available]medium10aromatic ketone
bifemelane[no description available]medium10diarylmethane
vigabatrin[no description available]medium10gamma-amino acidanticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
physostigmine[no description available]medium10carbamate ester;
indole alkaloid		antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic
kainic acid[no description available]medium20dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist
naadp[no description available]medium10nicotinic acid dinucleotidecalcium channel agonist;
metabolite;
signalling molecule
nadp[no description available]medium10
isoproterenol[no description available]medium10catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent
taurine[no description available]medium20amino sulfonic acid;
zwitterion		antioxidant;
Escherichia coli metabolite;
glycine receptor agonist;
human metabolite;
mouse metabolite;
nutrient;
radical scavenger;
Saccharomyces cerevisiae metabolite
diguanosine pentaphosphate[no description available]medium10
1-aminobenzotriazole[no description available]medium10
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid[no description available]medium30non-proteinogenic alpha-amino acid
adenine[no description available]medium206-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
valerates[no description available]medium10short-chain fatty acid anion;
straight-chain saturated fatty acid anion		plant metabolite
potassium cyanide[no description available]medium10cyanide salt;
one-carbon compound;
potassium salt		EC 1.15.1.1 (superoxide dismutase) inhibitor;
EC 1.9.3.1 (cytochrome c oxidase) inhibitor;
neurotoxin
bafilomycin a[no description available]medium10
nitric acid[no description available]medium10nitrogen oxoacidprotic solvent;
reagent
thymidine[no description available]medium30pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
snx 230[no description available]medium10
4-aminopyridine[no description available]medium10aminopyridine;
aromatic amine		avicide;
orphan drug;
potassium channel blocker
lucifer yellow[no description available]medium10organic lithium saltfluorochrome
cocaine[no description available]medium10benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid		adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic
glyoxylic acid[no description available]medium102-oxo monocarboxylic acid;
aldehydic acid		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
clopidogrel[no description available]medium10methyl ester;
monochlorobenzenes;
thienopyridine		anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
ticlopidine[no description available]medium10monochlorobenzenes;
thienopyridine		anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor
vanadates[no description available]medium10trivalent inorganic anion;
vanadium oxoanion		EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor
pituitrin[no description available]medium40
evans blue[no description available]medium20organic sodium saltfluorochrome;
histological dye;
sodium channel blocker;
teratogenic agent
purine[no description available]medium10purine
trypan blue[no description available]medium20
congo red[no description available]medium10bis(azo) compound
inositol[no description available]medium10cyclitol;
hexol
2,3-diphosphoglycerate[no description available]medium10bisphosphoglyceric acid;
tetronic acid derivative		human metabolite
lysine[no description available]medium10aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid		algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
oligonucleotides[no description available]medium10
thioinosine[no description available]medium10
4-nitrobenzylthioinosine[no description available]medium10purine nucleoside
nitrendipine[no description available]medium10C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester		antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent
tetraethylammonium[no description available]medium20quaternary ammonium ion
guanethidine[no description available]medium30azocanes;
guanidines		adrenergic antagonist;
antihypertensive agent;
sympatholytic agent
isatin[no description available]medium20indoledioneEC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite
2,2'-pyridylisatogen tosylate[no description available]medium10
diadenosine triphosphate[no description available]medium20diadenosyl triphosphatemouse metabolite
diethyl pyrocarbonate[no description available]medium10acyclic carboxylic anhydride
ouabain[no description available]medium2011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
scopolamine hydrobromide[no description available]medium10
2-chloro-atp[no description available]medium30
amphotericin b[no description available]medium20antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
glucose, (beta-d)-isomer[no description available]medium10D-glucopyranoseepitope;
mouse metabolite
octyl glucoside[no description available]medium10beta-D-glucosideplant metabolite
p(3)-1-(2-nitro)phenylethyladenosine 5'-triphosphate[no description available]medium10
clomipramine[no description available]medium10quaternary ammonium saltfluorochrome
adenosine-5'-(n-ethylcarboxamide)[no description available]medium20adenosines;
monocarboxylic acid amide		adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent
phosphorus radioisotopes[no description available]medium10
9-(2-hydroxy-3-nonyl)adenine[no description available]medium10
nicardipine[no description available]medium10benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound
talipexole[no description available]medium10azepine
uniblue a[no description available]medium10
reactive red 2[no description available]medium10
bradykinin[no description available]medium10oligopeptidehuman blood serum metabolite;
vasodilator agent
diadenosine 5',5''''-p1,p6-hexaphosphate[no description available]medium20diadenosyl hexaphosphatevasoconstrictor agent
chlorisondamine[no description available]medium10isoindoles
alosetron[no description available]medium10imidazoles;
pyridoindole		antiemetic;
gastrointestinal drug;
serotonergic antagonist
ziconotide[no description available]medium10
2-methyl-5-ht[no description available]medium10tryptaminesserotonergic agonist
men 11420[no description available]medium10
gr 82334[no description available]medium20
physalaemin[no description available]medium20
cadmium chloride[no description available]medium10cadmium coordination entity
felodipine[no description available]medium10dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester		anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent
cytidylyl-3',5'-adenosine[no description available]medium10nucleoside analogue;
purines
1229u91[no description available]medium10
formaldehyde[no description available]medium10aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
adenosine 5'-tetraphosphate[no description available]medium10adenosine 5'-phosphate;
purine ribonucleoside 5'-tetraphosphate
sincalide[no description available]medium10oligopeptide
senktide[no description available]medium10
calmidazolium[no description available]medium10imidazolium ionapoptosis inducer;
calmodulin antagonist
kn 04[no description available]medium20
melatonin[no description available]medium10acetamides;
tryptamines		anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger
n-acetylserotonin[no description available]medium20acetamides;
N-acylserotonin;
phenols		antioxidant;
human metabolite;
mouse metabolite;
tropomyosin-related kinase B receptor agonist
theobromine[no description available]medium30dimethylxanthineadenosine receptor antagonist;
bronchodilator agent;
food component;
human blood serum metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent
3,7-dimethyl-1-propargylxanthine[no description available]medium30
adenosine 3'-phosphate-5'-phosphate[no description available]medium10adenosine bisphosphateEscherichia coli metabolite;
mouse metabolite
phenyl acetate[no description available]medium10benzenes;
phenyl acetates
coenzyme a[no description available]medium10adenosine 3',5'-bisphosphatecoenzyme;
Escherichia coli metabolite;
mouse metabolite
mercaptoethanol[no description available]medium10alkanethiol;
primary alcohol		geroprotector
bisindolylmaleimide i[no description available]medium10
8-(3-chlorostyryl)caffeine[no description available]medium10monochlorobenzenes;
trimethylxanthine		adenosine A2A receptor antagonist;
EC 1.4.3.4 (monoamine oxidase) inhibitor
clonidine[no description available]medium20clonidine;
imidazoline
reserpine[no description available]medium10alkaloid ester;
methyl ester;
yohimban alkaloid		adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic
oxymetazoline[no description available]medium10carboxamidine;
imidazolines;
phenols		alpha-adrenergic agonist;
nasal decongestant;
sympathomimetic agent;
vasoconstrictor agent
levamisole[no description available]medium106-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazoleantinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator
beta-glycerophosphoric acid[no description available]medium10glycerol monophosphateEscherichia coli metabolite;
plant metabolite
charybdotoxin[no description available]medium10
cardiovascular agents[no description available]medium10
amphetamine[no description available]medium20primary amine
5-(n,n-hexamethylene)amiloride[no description available]medium10aromatic amine;
azepanes;
guanidines;
monocarboxylic acid amide;
organochlorine compound;
pyrazines		antineoplastic agent;
apoptosis inducer;
odorant receptor antagonist;
sodium channel blocker
rutecarpine[no description available]medium10beta-carbolines
evodiamine[no description available]medium10beta-carbolines
adamantane[no description available]medium10adamantanes;
polycyclic alkane
u 37883a[no description available]medium10
dinoprost[no description available]medium10monocarboxylic acid;
prostaglandins Falpha		human metabolite;
mouse metabolite
gr 63799x[no description available]medium10
rolipram[no description available]medium10pyrrolidin-2-onesantidepressant;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
zaprinast[no description available]medium10triazolopyrimidines
acetic acid[no description available]medium10monocarboxylic acidantimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent
4-phenolsulfonic acid[no description available]low00arenesulfonic acid
4-hydroxy-3-methoxybenzene-1-sulfonic acid[no description available]low00arenesulfonic acid;
guaiacols		expectorant
4-toluenesulfonic acid[no description available]low00arenesulfonic acid;
toluenes
ovex[no description available]low00arenesulfonic acid
2,4-dinitrobenzenesulfonic acid[no description available]low00arenesulfonic acid;
C-nitro compound
sulfosalicylic acid[no description available]low00arenesulfonic acid;
benzoic acids;
phenols		metabolite
1,2-naphthoquinone-4-sulfonate[no description available]low00arenesulfonic acid;
naphthalenone		colorimetric reagent
trinitrobenzenesulfonic acid[no description available]low00arenesulfonic acid;
C-nitro compound		epitope;
explosive;
reagent
4-chloromercuribenzenesulfonate[no description available]low00arenesulfonic acid;
arylmercury compound
azuletil[no description available]low00arenesulfonic acid;
azulenes		anti-ulcer drug;
thromboxane A2 antagonist
anthraquinone-2,6-disulfonate[no description available]low00anthraquinone;
arenesulfonic acid
bathocuproine disulfonate[no description available]low00arenesulfonic acid;
phenanthrolines		chelator
1,3-dimethyl-2,4-dioxo-5-pyrimidinesulfonic acid phenyl ester[no description available]low00arenesulfonic acid
azobenzene[no description available]low00azobenzenes
p-dimethylaminoazobenzene[no description available]low00azobenzenes
disperse orange 3[no description available]low00azobenzenes;
primary arylamine		allergen;
dye
ethoxazene[no description available]low00azobenzenes
c.i. solvent yellow 56[no description available]low00azobenzenes;
substituted aniline;
tertiary amino compound		dye;
mutagen
olsalazine[no description available]low00azobenzenes;
dicarboxylic acid		non-steroidal anti-inflammatory drug;
prodrug
sudan black b[no description available]low00azobenzenes;
bis(azo) compound;
perimidines		histological dye
scarlet red[no description available]low00azobenzenes;
bis(azo) compound;
naphthols		carcinogenic agent;
fluorochrome;
histological dye
sudan iii[no description available]low00azobenzenes;
bis(azo) compound;
naphthols		carcinogenic agent;
fluorochrome;
histological dye
reactive red 120 dye[no description available]low00azobenzenes;
bis(azo) compound;
chloro-1,3,5-triazine;
diamino-1,3,5-triazine;
naphthalenesulfonic acid		dye
ponceau mx[no description available]low00azobenzenes;
naphthalenesulfonic acid;
naphthols		carcinogenic agent;
cardiotoxic agent
bis-q[no description available]low00azobenzenes
butanoic acid [2-oxo-2-(4-phenyldiazenylanilino)ethyl] ester[no description available]low00azobenzenes
2-[4-(dimethylamino)phenyl]azobenzoic acid [2-(1-azepanyl)-2-oxoethyl] ester[no description available]low00azobenzenes
pyridoxal[no description available]low00hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pyridoxamine phosphate[no description available]low00aminoalkylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6 phosphate		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
pyridoxine[no description available]low00hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6		cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine[no description available]low00methylpyridines;
phenylpyridine;
tetrahydropyridine		neurotoxin
4-deoxypyridoxine[no description available]low00hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine		metabolite
pyridoxic acid[no description available]low00hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6		human urinary metabolite;
mouse metabolite
2,4-dimethylpyridine[no description available]low00methylpyridines
2,6-lutidine[no description available]low00methylpyridines
gamma-collidine[no description available]low00methylpyridines
1-methylpyridinium[no description available]low00methylpyridines
pyrithioxin[no description available]low00methylpyridines
n'-methyl-2-pyridone-5-carboxamide[no description available]low00methylpyridines;
pyridinecarboxamide;
pyridone		metabolite;
mouse metabolite
pyritinol hydrochloride[no description available]low00methylpyridines
ac 263,222[no description available]low00imidazolines;
imidazolone;
methylpyridines;
pyridinemonocarboxylic acid
2-(Hydroxymethyl)-6-methylpyridin-3-ol[no description available]low00methylpyridines
latrepirdine[no description available]low00methylpyridines;
pyridoindole		geroprotector
2-methyl-3-hydroxypyridine-5-carboxylic acid[no description available]low00methylpyridines;
monohydroxypyridine
5-bromo-N-(5-methyl-2-pyridinyl)-2-thiophenesulfonamide[no description available]low00methylpyridines
1-(6-methyl-2-pyridinyl)-3-(2-phenylethyl)thiourea[no description available]low00methylpyridines
5-methyl-7-(trifluoromethyl)-2-thiazolo[4,5-b]pyridinamine[no description available]low00methylpyridines
6-methyl-2-(phenylethynyl)pyridine[no description available]low00acetylenic compound;
methylpyridines		anxiolytic drug;
metabotropic glutamate receptor antagonist
piericidin a[no description available]low00aromatic ether;
methylpyridines;
monohydroxypyridine;
secondary allylic alcohol		antimicrobial agent;
bacterial metabolite;
EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor;
mitochondrial respiratory-chain inhibitor
3-hydroxy-2-methyl-1-(phenylmethyl)-4-pyridinone[no description available]low00methylpyridines
sb-505124[no description available]low00benzodioxole;
imidazoles;
methylpyridines		TGFbeta receptor antagonist
ly-2157299[no description available]low00aromatic amide;
methylpyridines;
monocarboxylic acid amide;
pyrrolopyrazole;
quinolines		antineoplastic agent;
TGFbeta receptor antagonist
2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide[no description available]low00aromatic ether;
methylpyridines;
olefinic compound;
quinazolines;
secondary amino compound;
secondary carboxamide;
toluenes
gsk2656157[no description available]low00biaryl;
indoles;
methylpyridines;
organofluorine compound;
pyrrolopyrimidine;
tertiary carboxamide		antineoplastic agent;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
PERK inhibitor
sotorasib[no description available]low00acrylamides;
methylpyridines;
monofluorobenzenes;
N-acylpiperazine;
phenols;
pyridopyrimidine;
tertiary amino compound;
tertiary carboxamide		antineoplastic agent
pyridoxamine[no description available]low00aminoalkylpyridine;
hydroxymethylpyridine;
monohydroxypyridine;
vitamin B6		Escherichia coli metabolite;
human metabolite;
iron chelator;
mouse metabolite;
nephroprotective agent;
plant metabolite;
Saccharomyces cerevisiae metabolite
pyrithione[no description available]low00monohydroxypyridine;
pyridinethione		ionophore
3-hydroxypyridine[no description available]low00monohydroxypyridine
2-hydroxypyridine[no description available]low00monohydroxypyridineplant metabolite
4-hydroxypyridine[no description available]low004-pyridones;
monohydroxypyridine
3-hydroxypicolinic acid[no description available]low00monocarboxylic acid;
monohydroxypyridine		MALDI matrix material
2-amino-3-hydroxypyridine[no description available]low00aminopyridine;
monohydroxypyridine
6-hydroxynicotinic acid[no description available]low00monohydroxypyridineArabidopsis thaliana metabolite;
human urinary metabolite;
mouse metabolite
6-hydroxynicotine[no description available]low00monohydroxypyridine
ilicicolin h[no description available]low00aromatic ketone;
carbobicyclic compound;
ilicicolin;
monohydroxypyridine;
octahydronaphthalenes;
phenols;
pyridone		antimicrobial agent;
mitochondrial respiratory-chain inhibitor
3-pyridinaldehyde[no description available]low00pyridinecarbaldehyde
pyridine-2-carboxaldehyde[no description available]low00pyridinecarbaldehyde
pyridoxal phosphate[no description available]low00pyridinecarbaldehyde
benphothiamine[no description available]low00aminopyrimidine;
formamides;
organic phosphate;
thioester		antioxidant;
immunological adjuvant;
nutraceutical;
protective agent;
provitamin B1
chlorfenvinphos[no description available]low00dichlorobenzene;
organic phosphate;
organochlorine acaricide;
organochlorine insecticide;
organophosphate insecticide		agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor
psilocybin[no description available]low00organic phosphate;
tertiary amino compound;
tryptamine alkaloid		fungal metabolite;
hallucinogen;
prodrug;
serotonergic agonist
diazoxon[no description available]low00organic phosphate;
pyrimidines		marine xenobiotic metabolite
baeocystin[no description available]low00organic phosphate;
secondary amino compound;
tryptamine alkaloid		fungal metabolite;
hallucinogen
carboxy phosphate[no description available]low00acyclic mixed acid anhydride;
one-carbon compound;
organic phosphate
VPC 23019[no description available]low00aromatic amide;
D-serine derivative;
organic phosphate;
phosphoric ester;
secondary carboxamide		sphingosine-1-phosphate receptor 1 antagonist;
sphingosine-1-phosphate receptor 3 antagonist
ConditionIndicatedRelationship StrengthStudiesTrials
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Contact Dermatitis0low10
Dermatitis Venenata0low10
Dermatitis, Contact0low10
Disease Models, Animal0low20
Eczema, Contact0low10
Fever, Zika0low10
Hypersensitivity, Contact0low10
Itching0low10
Pruritis0low10
Pruritus0low10
Sensitivity, Contact0low10
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10
Ache0low80
Achondroplasia0low10
Achondroplasia, Severe, With Developmental Delay And Acanthosis Nigricans0low10
Acidosis0low10
Acute Brain Injuries0low40
Acute Hypercapnic Respiratory Failure0low10
Acute Hypoxemic Respiratory Failure0low10
Acute Post-operative Pain0low10
Acute Postoperative Pain0low10
Age-Related Macular Degeneration0low10
Age-Related Maculopathies0low10
Age-Related Maculopathy0low10
Aggression0low10
Aging0low40
Allergic Reaction0low10
Allergy0low10
Allergy, Food0low10
Allodynia0low70
Allodynia, Mechanical0low70
Allodynia, Tactile0low70
Allodynia, Thermal0low70
Alloxan Diabetes0low10
ALS - Amyotrophic Lateral Sclerosis0low10
Amyotrophic Lateral Sclerosis0low10
Amyotrophic Lateral Sclerosis With Dementia0low10
Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex 10low10
Amyotrophic Lateral Sclerosis, Guam Form0low10
Amyotrophic Lateral Sclerosis, Parkinsonism-Dementia Complex of Guam0low10
Anaplastic Astrocytoma0low20
Anemia, Fanconi0low10
Anesthesia0low20
Angiospasm, Intracranial0low10
Anoxemia0low60
Anoxia0low60
Anoxia-Ischemia, Brain0low10
Anoxia-Ischemia, Cerebral0low10
Anoxia, Brain0low20
Anoxia, Cerebral0low20
Anoxic Brain Damage0low20
Anoxic Encephalopathy0low20
Anoxic-Ischemic Encephalopathy0low10
Anterior Circulation Transient Ischemic Attack0low10
Anterior Ischemic Optic Neuropathy0low10
Apnea0low10
Apoplexy0low10
Arrhythmia0low10
Arrhythmias, Cardiac0low10
Arrythmia0low10
Arteriosclerosis0low10
Arthralgia0low10
Arthritis0low30
Astrocytoma0low20
Astrocytoma, Grade I0low20
Astrocytoma, Grade II0low20
Astrocytoma, Grade III0low20
Astrocytoma, Protoplasmic0low20
Astrocytoma, Subependymal Giant Cell0low20
Astrocytosis0low60
Astroglioma0low20
Astrogliosis0low60
Asymmetric Diabetic Proximal Motor Neuropathy0low10
Atherogenesis0low10
Atherosclerosis0low10
Atrioventricular Nodal Re-Entrant Tachycardia0low10
Atrioventricular Reentrant Tachycardia0low10
Atrophy0low10
Aura0low10
Awakening Epilepsy0low10
Benign Neoplasms, Brain0low20
Bladder Disorder, Neurogenic0low10
Bladder Neck Obstruction0low10
Bladder Neurogenesis0low10
Bladder Outlet Obstruction0low10
Bladder, Neurogenic0low10
Bladder, Overactive0low10
Blood Pressure, High0low30
Blood Pressure, Low0low20
Bowel Diseases, Inflammatory0low10
Bradyarrhythmia0low20
Bradyarrhythmias0low20
Bradycardia0low20
Brain Anoxia0low20
Brain Anoxia-Ischemia0low10
Brain Cancer0low20
Brain Hypoxia0low20
Brain Hypoxia-Ischemia0low10
Brain Injuries0low40
Brain Injuries, Acute0low40
Brain Injuries, Focal0low40
Brain Ischemia0low10
Brain Ischemia-Anoxia0low10
Brain Ischemia-Hypoxia0low10
Brain Lacerations0low40
Brain Metastases0low20
Brain Neoplasm, Primary0low20
Brain Neoplasms0low20
Brain Neoplasms, Benign0low20
Brain Neoplasms, Malignant0low20
Brain Neoplasms, Malignant, Primary0low20
Brain Neoplasms, Primary Malignant0low20
Brain Stem Ischemia, Transient0low10
Brain Stem Transient Ischemic Attack0low10
Brain TIA0low10
Brain Tumor, Primary0low20
Brain Tumor, Recurrent0low20
Brain Tumors0low20
Brainstem Ischemia, Transient0low10
Brainstem Transient Ischemic Attack0low10
Bruise0low10
Cancer of Brain0low20
Cancer of Lung0low10
Cancer of the Brain0low20
Cancer of the Lung0low10
Carcinoma, Thymic0low10
Cardiac Arrhythmia0low10
Cardiac Arrhythmias0low10
Cardiac Dysrhythmia0low10
Cardiac Output, Low0low10
Cardiac Remodeling, Ventricular0low20
Cardiomyopathies0low10
Cardiomyopathies, Primary0low10
Cardiomyopathies, Secondary0low10
Cardiovascular Diseases0low10
Cardiovascular Stroke0low20
Carotid Circulation Transient Ischemic Attack0low10
Cerebral Angiospasm0low10
Cerebral Anoxia0low20
Cerebral Anoxia-Ischemia0low10
Cerebral Artery Spasm0low10
Cerebral Astrocytoma0low20
Cerebral Hypoxia0low20
Cerebral Hypoxia-Ischemia0low10
Cerebral Infarction, Middle Cerebral Artery0low20
Cerebral Ischemia0low10
Cerebral Ischemia-Anoxia0low10
Cerebral Ischemia-Hypoxia0low10
Cerebral Ischemia, Transient0low10
Cerebral Stroke0low10
Cerebral Vasospasm0low10
Cerebrovascular Accident0low10
Cerebrovascular Accident, Acute0low10
Cerebrovascular Apoplexy0low10
Cerebrovascular Spasm0low10
Cerebrovascular Stroke0low10
Charcot Disease0low10
Childhood Cerebral Astrocytoma0low20
Choroid Neovascularization0low20
Choroidal Neovascularization0low20
Chronic Disease0low20
Chronic Illness0low20
Chronic Post-operative Pain0low10
Chronic Post-surgical Pain0low10
Chronic Postoperative Pain0low10
Chronic Postsurgical Pain0low10
Chronically Ill0low20
Cognition Disorders0low10
Colitis0low10
Colitis, Mucous0low20
Colon, Irritable0low20
Congenital Zika Syndrome0low10
Congenital Zika Virus Infection0low10
Contusions0low10
Coronary Disease0low10
Coronary Heart Disease0low10
Cough0low10
Craniofacial Pain0low10
Crescendo Transient Ischemic Attacks0low10
Crush Fractures0low10
Crush Injuries0low10
CVA (Cerebrovascular Accident)0low10
Cystitis0low40
DDD MPGNII0low10
Decerebrate Posturing0low50
Decerebrate State0low50
Decorticate Rigidity0low50
Decorticate State0low50
Deficiency, Oxygen0low60
Degenerative Diseases, Central Nervous System0low10
Degenerative Diseases, Nervous System0low10
Degenerative Diseases, Neurologic0low10
Degenerative Diseases, Spinal Cord0low10
Degenerative Neurologic Diseases0low10
Degenerative Neurologic Disorders0low10
Dementia With Amyotrophic Lateral Sclerosis0low10
Dense Deposit Disease0low10
Depression0low10
Diabetes Mellitus0low10
Diabetes Mellitus, Adult-Onset0low10
Diabetes Mellitus, Experimental0low10
Diabetes Mellitus, Ketosis-Resistant0low10
Diabetes Mellitus, Maturity-Onset0low10
Diabetes Mellitus, Non Insulin Dependent0low10
Diabetes Mellitus, Non-Insulin-Dependent0low10
Diabetes Mellitus, Noninsulin Dependent0low10
Diabetes Mellitus, Noninsulin-Dependent0low10
Diabetes Mellitus, Slow-Onset0low10
Diabetes Mellitus, Stable0low10
Diabetes Mellitus, Type 20low10
Diabetes Mellitus, Type II0low10
Diabetic Amyotrophy0low10
Diabetic Angiopathies0low10
Diabetic Asymmetric Polyneuropathy0low10
Diabetic Autonomic Neuropathy0low10
Diabetic Mononeuropathy0low10
Diabetic Mononeuropathy Simplex0low10
Diabetic Neuralgia0low10
Diabetic Neuropathies0low10
Diabetic Neuropathy, Painful0low10
Diabetic Polyneuropathy0low10
Diabetic Vascular Complications0low10
Diabetic Vascular Diseases0low10
Disease Exacerbation0low10
Disease Models, Animal0low320
Disease Progression0low10
Diseases, Peripheral Vascular0low10
Electrolytes0low10
Embolic Infarction, Middle Cerebral Artery0low20
Embolus, Middle Cerebral Artery0low20
Emesis0low10
Encephalopathy, Anoxic-Ischemic0low10
Encephalopathy, Hypoxic0low20
Encephalopathy, Hypoxic-Ischemic0low10
Encephalopathy, Ischemic0low10
Endotoxemia0low10
Epilepsy0low10
Epilepsy, Cryptogenic0low10
Epileptiform Neuralgia0low10
Experimental Diabetes Mellitus0low10
Extravascular Hemolysis0low50
Face Pain0low10
Facial Pain0low10
Fanconi Anemia0low10
Fanconi Hypoplastic Anemia0low10
Fanconi Pancytopenia0low10
Fanconi Panmyelopathy0low10
Fanconi's Anemia0low10
Fasting Hypoglycemia0low10
Fever0low20
Fever, Zika0low10
Fibrillary Astrocytoma0low20
Focal Brain Injuries0low40
Food Allergy0low10
Food Hypersensitivity0low10
Fothergill Disease0low10
Gehrig's Disease0low10
Gemistocytic Astrocytoma0low20
Glial Cell Tumors0low50
Glial Scar0low60
Glioma0low50
Glioma, Astrocytic0low20
Gliosis0low60
Glomerulonephritis, Hypocomplementemic0low10
Glomerulonephritis, Membranoproliferative0low10
Glomerulonephritis, Mesangiocapillary0low10
Graft vs Host Disease0low10
Graft-Versus-Host Disease0low10
Graft-vs-Host Disease0low10
Guam Disease0low10
Guam Form of Amyotrophic Lateral Sclerosis0low10
Haemolysis0low50
Heart Attack0low20
Heart Disease, Ischemic0low20
Hemolysis0low50
Hemorrhage, Subarachnoid0low20
Homologous Wasting Disease0low10
Human Trichinellosis0low10
Hyperalgesia0low70
Hyperalgesia, Mechanical0low70
Hyperalgesia, Primary0low70
Hyperalgesia, Secondary0low70
Hyperalgesia, Tactile0low70
Hyperalgesia, Thermal0low70
Hyperalgesic Sensations0low70
Hyperalgia0low70
Hyperalgia, Mechanical0low70
Hyperalgia, Primary0low70
Hyperalgia, Secondary0low70
Hypercapnia0low50
Hypercapnic Acute Respiratory Failure0low10
Hypercapnic Respiratory Failure0low10
Hyperoxia0low10
Hyperplasia0low10
Hypersensitivity0low10
Hypersensitivity, Food0low10
Hypertension0low30
Hypertrophy0low20
Hyperventilation0low10
Hypoglycemia0low10
Hypotension0low20
Hypotension, Vascular0low20
Hypoventilation0low10
Hypoxemia0low60
Hypoxemic Acute Respiratory Failure0low10
Hypoxemic Respiratory Failure0low10
Hypoxia0low60
Hypoxia-Ischemia, Brain0low10
Hypoxia-Ischemia, Cerebral0low10
Hypoxia, Brain0low20
Hypoxia, Cerebral0low20
Hypoxic Brain Damage0low20
Hypoxic Encephalopathy0low20
Hypoxic-Ischemic Encephalopathy0low10
Idiopathic Parkinson Disease0low10
Idiopathic Parkinson's Disease0low10
Idiopathic Ventricular Tachycardia0low10
Infarction, Middle Cerebral Artery0low20
Inflammation0low70
Inflammatory Bowel Diseases0low10
Injuries0low10
Injuries and Wounds0low10
Injuries, Acute Brain0low40
Injuries, Brain0low40
Injuries, Spinal Cord0low50
Injuries, Wounds0low10
Injury, Myocardial Reperfusion0low10
Innate Inflammatory Response0low70
Intracranial Angiospasm0low10
Intracranial Astrocytoma0low20
Intracranial Neoplasms0low20
Intracranial Vascular Spasm0low10
Intracranial Vasospasm0low10
Intraocular Pressure0low10
Intravascular Hemolysis0low50
Irritable Bowel Syndrome0low20
Ischemia0low10
Ischemia-Anoxia, Brain0low10
Ischemia-Anoxia, Cerebral0low10
Ischemia-Hypoxia, Brain0low10
Ischemia-Hypoxia, Cerebral0low10
Ischemia, Cerebral0low10
Ischemia, Myocardial0low20
Ischemic Attack, Transient0low10
Ischemic Encephalopathy0low10
Ischemic Heart Disease0low20
Ischemic Optic Neuropathy0low10
Ischemic-Hypoxic Encephalopathy0low10
Joint Pain0low10
Juvenile Pilocytic Astrocytoma0low20
Left Middle Cerebral Artery Infarction0low20
Left Ventricle Remodeling0low20
Left Ventricular Remodeling0low20
Lesion of Sciatic Nerve0low10
Lewy Body Parkinson Disease0low10
Lewy Body Parkinson's Disease0low10
Lou Gehrig Disease0low10
Lou Gehrig's Disease0low10
Lou-Gehrigs Disease0low10
Low Blood Pressure0low20
Low Cardiac Output0low10
Low Cardiac Output Syndrome0low10
Lung Cancer0low10
Lung Neoplasms0low10
Macular Degeneration0low10
Macular Degeneration, Age-Related0low10
Macular Dystrophy0low10
Maculopathies, Age-Related0low10
Maculopathy0low10
Maculopathy, Age-Related0low10
Malignant Glioma0low50
Malignant Neoplasms, Brain0low20
Malignant Primary Brain Neoplasms0low20
Malignant Primary Brain Tumors0low20
Maturity-Onset Diabetes0low10
Maturity-Onset Diabetes Mellitus0low10
MCA Infarct0low20
MCA Infarction0low20
Mechanical Allodynia0low70
Mechanical Hyperalgesia0low70
Membranoproliferative Glomerulonephritis0low10
Membranoproliferative Glomerulonephritis Type II0low10
Membranoproliferative Glomerulonephritis, Type I0low10
Membranoproliferative Glomerulonephritis, Type II0low10
Membranoproliferative Glomerulonephritis, Type III0low10
Mesangiocapillary Glomerulonephritis0low10
Mesangiocapillary Glomerulonephritis, Type I0low10
Mesangiocapillary Glomerulonephritis, Type II0low10
Metabolic Acidosis0low10
Microangiopathy, Diabetic0low10
Middle Cerebral Artery Circulation Infarction0low20
Middle Cerebral Artery Embolic Infarction0low20
Middle Cerebral Artery Embolus0low20
Middle Cerebral Artery Infarction0low20
Middle Cerebral Artery Occlusion0low20
Middle Cerebral Artery Stroke0low20
Middle Cerebral Artery Syndrome0low20
Middle Cerebral Artery Thrombosis0low20
Middle Cerebral Artery Thrombotic Infarction0low20
Mixed Glioma0low50
MODY0low10
Mononeuropathy, Diabetic0low10
Motor Neuron Disease, Amyotrophic Lateral Sclerosis0low10
MPGN0low10
MPGNII0low10
Muscle Contraction0low600
Muscle Relaxation0low220
Muscle Spasm0low10
Muscular Spasm0low10
Myelopathy, Traumatic0low50
Myocardial Diseases0low10
Myocardial Diseases, Primary0low10
Myocardial Diseases, Secondary0low10
Myocardial Infarct0low20
Myocardial Infarction0low20
Myocardial Ischemia0low20
Myocardial Ischemic Reperfusion Injury0low10
Myocardial Remodeling, Ventricular0low20
Myocardial Reperfusion Injury0low10
Myocardiopathies0low10
Myofacial Pain0low10
NAION0low10
Nasal Catarrh0low10
Nausea0low10
Necrosis0low10
Neoplasms, Brain0low20
Neoplasms, Brain, Benign0low20
Neoplasms, Brain, Malignant0low20
Neoplasms, Brain, Primary0low20
Neoplasms, Intracranial0low20
Neoplasms, Lung0low10
Neoplasms, Pulmonary0low10
Neovascularization, Choroid0low20
Neovascularization, Choroidal0low20
Neovascularization, Optic Disc0low10
Neovascularization, Retinal0low10
Nerve Degeneration0low10
Nervous System Degenerative Diseases0low10
Neuralgia-Neuritis, Sciatic Nerve0low10
Neuralgia, Diabetic0low10
Neuralgic Facial Pain0low10
Neuroblastoma0low20
Neurodegenerative Diseases0low10
Neurodegenerative Disorders0low10
Neurogenic Bladder0low10
Neurogenic Bladder Disorder0low10
Neurogenic Bladder, Atonic0low10
Neurogenic Bladder, Spastic0low10
Neurogenic Bladder, Uninhibited0low10
Neurogenic Dysfunction of the Urinary Bladder0low10
Neurogenic Urinary Bladder Disorder0low10
Neurogenic Urinary Bladder, Atonic0low10
Neurogenic Urinary Bladder, Spastic0low10
Neurogenic Urinary Bladder, Uninhibited0low10
Neurologic Degenerative Conditions0low10
Neurologic Degenerative Diseases0low10
Neurologic Diseases, Degenerative0low10
Neuron Degeneration0low10
Neuropathic Bladder0low10
NIDDM0low10
Nonarteritic Anterior Ischemic Optic Neuropathy0low10
Noninsulin-Dependent Diabetes Mellitus0low10
Nonsustained Ventricular Tachycardia0low10
Occlusion, Middle Cerebral Artery0low20
Oligoastrocytoma, Mixed0low20
Optic Disc Neovascularization0low10
Optic Disk Neovascularization0low10
Optic Ischaemic Neuropathy0low10
Optic Ischemic Neuropathy0low10
Optic Nerve Ischemia0low10
Optic Neuropathy, Anterior Ischemic0low10
Optic Neuropathy, Ischemic0low10
Optic Neuropathy, Posterior Ischemic0low10
Orofacial Pain0low10
Overactive Bladder0low10
Overactive Detrusor0low10
Overactive Detrusor Function0low10
Overactive Urinary Bladder0low10
Overinclusion0low10
Oxygen Deficiency0low60
Pain0low80
Pain, Burning0low80
Pain, Crushing0low80
Pain, Facial0low10
Pain, Migratory0low80
Pain, Post-operative0low10
Pain, Postoperative0low10
Pain, Radiating0low80
Pain, Splitting0low80
Paralysis Agitans0low10
Parkinson Disease0low10
Parkinson Disease, Idiopathic0low10
Parkinson's Disease0low10
Parkinson's Disease, Idiopathic0low10
Parkinson's Disease, Lewy Body0low10
Paroxysmal Supraventricular Tachycardia0low10
Perinatal Subarachnoid Hemorrhage0low20
Peripheral Angiopathies0low10
Peripheral Nerve Diseases0low20
Peripheral Nerve Injuries0low10
Peripheral Nerve Injury0low10
Peripheral Nervous System Disease0low20
Peripheral Nervous System Diseases0low20
Peripheral Nervous System Disorders0low20
Peripheral Neuropathies0low20
Peripheral Vascular Diseases0low10
Persistent Postsurgical Pain0low10
Pigmentary Retinopathy0low10
Pilocytic Astrocytoma0low20
PNS (Peripheral Nervous System) Diseases0low20
PNS Diseases0low20
Polyarthralgia0low10
Polyarthritis0low30
Post-operative Pain0low10
Post-operative Pain, Acute0low10
Post-operative Pain, Chronic0low10
Post-surgical Pain0low10
Post-Traumatic Myelopathy0low50
Postabsorptive Hypoglycemia0low10
Posterior Circulation Transient Ischemic Attack0low10
Posterior Ischemic Optic Neuropathy0low10
Postoperative Pain0low10
Postoperative Pain, Acute0low10
Postoperative Pain, Chronic0low10
Postprandial Hypoglycemia0low10
Postsurgical Pain0low10
Pregnancy0low40
Primary Brain Neoplasms0low20
Primary Malignant Brain Neoplasms0low20
Primary Malignant Brain Tumors0low20
Primary Myocardial Diseases0low10
Primary Parkinsonism0low10
Pulmonary Cancer0low10
Pulmonary Neoplasms0low10
Pyrexia0low20
Reactive Hypoglycemia0low10
Reperfusion Injury, Myocardial0low10
Research-Related Injuries0low10
Respiratory Depression0low10
Respiratory Failure0low10
Respiratory Insufficiency0low10
Retinal Degeneration0low10
Retinal Detachment0low10
Retinal Neovascularization0low10
Retinal Pigment Epithelial Detachment0low10
Retinitis Pigmentosa0low10
Rhinitis0low10
Right Middle Cerebral Artery Infarction0low20
Rigidity, Decerebrate0low50
Rigidity, Decorticate0low50
Runt Disease0low10
SADDAN0low10
SADDAN Dysplasia0low10
SAH (Subarachnoid Hemorrhage)0low20
Sciatic Nerve Diseases0low10
Sciatic Nerve Palsy0low10
Sciatic Neuritis0low10
Sciatic Neuropathy0low10
Sea Fan Neovascularization0low10
Secondary Myocardial Diseases0low10
Secondary Trigeminal Neuralgia0low10
Seizure Disorder0low10
Sensitivity and Specificity0low10
Severe Achondroplasia with Developmental Delay and Acanthosis Nigricans0low10
Skeleton-Skin-Brain Syndrome0low10
Spasm0low10
Spasm, Ciliary Body0low10
Spasm, Generalized0low10
Spinal Cord Contusion0low50
Spinal Cord Injuries0low50
Spinal Cord Laceration0low50
Spinal Cord Transection0low50
Spinal Cord Trauma0low50
Streptozocin Diabetes0low10
Streptozotocin Diabetes0low10
Stroke0low10
Stroke, Acute0low10
Stroke, Middle Cerebral Artery0low20
Subarachnoid Hemorrhage0low20
Subarachnoid Hemorrhage, Aneurysmal0low20
Subarachnoid Hemorrhage, Intracranial0low20
Subarachnoid Hemorrhage, Spontaneous0low20
Subendothelial Membranoproliferative Glomerulonephritis0low10
Subependymal Giant Cell Astrocytoma0low20
Suffering, Physical0low80
Symmetric Diabetic Proximal Motor Neuropathy0low10
Tachycardia, Ventricular0low10
Tactile Allodynia0low70
Tapetoretinal Degeneration0low10
Temporomandibular Disorders0low20
Temporomandibular Joint Diseases0low20
Temporomandibular Joint Disorders0low20
Thermal Allodynia0low70
Thrombosis, Middle Cerebral Artery0low20
Thrombotic Infarction, Middle Cerebral Artery0low20
Thymoma0low10
TIA (Transient Ischemic Attack)0low10
Tic Doloureux0low10
Tic Douloureux0low10
TMJ Diseases0low20
TMJ Disorders0low20
Transient Ischemic Attack0low10
Transient Ischemic Attack, Anterior Circulation0low10
Transient Ischemic Attack, Brain Stem0low10
Transient Ischemic Attack, Brainstem0low10
Transient Ischemic Attack, Carotid Circulation0low10
Transient Ischemic Attack, Posterior Circulation0low10
Transient Ischemic Attack, Vertebrobasilar Circulation0low10
Transient Ischemic Attacks, Crescendo0low10
Trauma0low10
Trichinelliasis0low10
Trichinellosis0low10
Trichinosis0low10
Trifacial Neuralgia0low10
Trigeminal Neuralgia0low10
Trigeminal Neuralgia, Idiopathic0low10
Trigeminal Neuralgia, Secondary0low10
Type 2 Diabetes0low10
Type 2 Diabetes Mellitus0low10
Type II MPGN0low10
Urinary Bladder Disorder, Neurogenic0low10
Urinary Bladder Neck Obstruction0low10
Urinary Bladder Neurogenesis0low10
Urinary Bladder Neurogenic Dysfunction0low10
Urinary Bladder, Neurogenic0low10
Urinary Bladder, Overactive0low10
Varices0low10
Varicose Veins0low10
Varix0low10
Vascular Accident, Brain0low10
Vascular Diseases, Peripheral0low10
Vascular Hypotension0low20
Vasospasm, Intracranial0low10
Ventilatory Depression0low10
Ventricle Remodeling0low20
Ventricular Remodeling0low20
Ventricular Tachyarrhythmias0low10
Ventricular Tachycardia0low10
Vertebrobasilar Circulation Transient Ischemic Attack0low10
Vestibular Diseases0low10
Vomiting0low10
Wounds0low10
Wounds and Injuries0low10
Wounds and Injury0low10
Wounds, Injury0low10
Wounds, Penetrating0low10
Zika Fever0low10
Zika Virus Disease0low10
Zika Virus Infection0low10
ZikV Infection0low10

Research Highlights

Safety/Toxicity (3)

ArticleYear
Ivermectin inhibits AMPA receptor-mediated excitotoxicity in cultured motor neurons and extends the life span of a transgenic mouse model of amyotrophic lateral sclerosis.
Neurobiology of disease, Volume: 25, Issue: 1		2007
Differences in the neurotoxicity profile induced by ATP and ATPgammaS in cultured cerebellar granule neurons.
Neurochemistry international, Volume: 47, Issue: 5		2005
P2 receptor antagonist PPADS confers neuroprotection against glutamate/NMDA toxicity.
Neuroscience letters, Mar-29, Volume: 377, Issue: 2		2005
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Long-term Use (1)

ArticleYear
P2X purinergic receptor-mediated ionic current in cardiac myocytes of calsequestrin model of cardiomyopathy: implications for the treatment of heart failure.
American journal of physiology. Heart and circulatory physiology, Volume: 292, Issue: 2		2007
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pharmacokinetics (3)

ArticleYear
Intracellular Ca2+ responses and cell volume regulation upon cholinergic and purinergic stimulation in an immortalized salivary cell line.
European journal of oral sciences, Volume: 118, Issue: 3		2010
Volume-activated chloride channels in mice Leydig cells.
Pflugers Archiv : European journal of physiology, Volume: 457, Issue: 2		2008
Characterization of volume-sensitive taurine- and Cl(-)-permeable channels.
The American journal of physiology, Volume: 273, Issue: 1 Pt 1		1997
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioavailability (3)

ArticleYear
Blunted coronary vasodilator response to uridine adenosine tetraphosphate in post-infarct remodeled myocardium is due to reduced P1 receptor activation.
Pharmacological research, Volume: 77		2013
Activation of P2Y receptor enhances high-molecular compound absorption from rat ileum.
The Journal of pharmacy and pharmacology, Volume: 58, Issue: 2		2006
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Dosage (9)

ArticleYear
P2X7 receptor antagonism increases regulatory T cells and reduces clinical and histological graft-versus-host disease in a humanised mouse model.
Clinical science (London, England : 1979), 02-12, Volume: 135, Issue: 3		2021
Osmosensitive response of glutamate in the substantia nigra.
Experimental neurology, Volume: 220, Issue: 2		2009
Existence of high and low affinity dinucleotides pentaphosphate-induced calcium responses in individual synaptic terminals and lack of correlation with the distribution of P2X1-7 subunits.
Neurochemistry international, Volume: 50, Issue: 4		2007
Contractile activity of ATP and diadenosine tetraphosphate on urinary bladder in the rat: role of A1- and P2X-purinoceptors and nitric oxide.
Autonomic & autacoid pharmacology, Volume: 27, Issue: 1		2007
Acidosis attenuates P2X purinergic vasoconstriction in skeletal muscle arteries.
American journal of physiology. Heart and circulatory physiology, Volume: 288, Issue: 1		2005
[Acceleration of ATP-induced contraction in the obstructed bladder of the rat].
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, Volume: 94, Issue: 3		2003
Excitatory effect of ATP on acutely dissociated ventromedial hypothalamic neurons of the rat.
Neuroscience, Volume: 105, Issue: 2		2001
The positive inotropic and chronotropic effects of evodiamine and rutaecarpine, indoloquinazoline alkaloids isolated from the fruits of Evodia rutaecarpa, on the guinea-pig isolated right atria: possible involvement of vanilloid receptors.
Planta medica, Volume: 67, Issue: 3		2001
Discrimination by PPADS between endothelial P2Y- and P2U-purinoceptors in the rat isolated mesenteric arterial bed.
British journal of pharmacology, Volume: 118, Issue: 2		1996
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]